Categories
Report

NNVC

***Sponsored by Interactive Offers, LLC

Targeted Virus-Killing Nanomedicines (PRNewsFoto/NanoViricides, Inc.)

CHECK OUT THE INVESTOR PRESENTATION HERE

‍

___________________________

Hello Everyone,

We havre something back on our our list for tomorrow’s session that has been familiar to our members over the past few months. This one has been moving and is sitting about 30-40 cents higher than the last time we profiled it.

Pull up NNVC ahead of tomorrow’s session.

Take a look at the chart below. This is one. is approaching the 52 week high……… in fact, in anothe month or so these levels would be the 52 week high.

It has closed green 11 of the last 15 sessions and is sitting right at resistance.

We really want to emphasize the need to research NNVC right here.

‍

NNVC looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.

‍NNVC is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV and other respiratory viruses!

Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031.

NANOVIRICIDES are better because they destroy viruses and their variants without relying on the patient’s immune system, thereby making them effective for populations that include geriatric and pediatric patients.

Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients..

Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.

NV-387 – A novel broad-spectrum antiviral

  • Since it is a potential cure for RSV infection, and since there is no non-toxic drug for general treatment of RSV infection at present; NV-387 meets an unmet need.
  • A therapeutic for treating measles is a completely missing link in the response the the current measles virus outbreak; NV-387 could meet this unmet need too.
  • The anti-Influenza activity of NV-387 given orally was substantially superior to all three of the approved anti-influenza drugs (Tamiflu, Rapivab, and Xofluza).
  • Bird flu is rampant in poultry in the USA leading to hen culling and soaring egg prices, resulting in a race to find a treatment that works; NV-387 can address it.
  • Long COVID also remains a problem for an estimated 17 million adults; an effective antiviral such as NV-387 has already delivered successful Phase 1 results.
  • While smallpox is eradicated in the USA, contagious monkeypox has appeared but there is no effective drug treatment for it and competitors clinical trials have failed; NV-387 is entering Phase 2 clinical trials for it.

NanoViricides, Inc. (NYSE American: NNVC)’s lead drug candidate NV-387 (drug product NV-CoV-2),  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, NNVC has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have decades of  effective usability against the target viruses similar to the life of current antibiotics against bacterial infections but in stark contrast to  current antiviral approaches.

A broad-spectrum antiviral drug such as NV-387 would be a highly desirable drug globally because it  would enable treatment by physicians of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of the drug.

NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells

Over 90% of human pathogenic viruses are known to use one or more “landing sites” that are in the Sulfated Proteoglycans (“SPG”) family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.

NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. We have accumulated substantial evidence that in lethal viral infection animal studies, NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents.

‍

Superior to Other Treatments???????????

NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus, as reported earlier. We believe that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections.

In treating Influenza, NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study, as previously reported. We believe that NV-387 is expected to possess strong antiviral activity against H5N1 “Bird Flu” as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387.

NNVC has also found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin.

Moreover, even novel viruses, whether from natural sources or bio-engineered, are expected to be susceptible to NV-387 if they employ SPG for gaining access to human cells to infect and cause disease. Thus, NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics.

NV-387 could thus be a single drug to treat all of the “tripledemic” viruses (COVID, RSV, FLU ), and more, when so approved!

Finally, NV-387 was at least as effective as the approved drug tecovitrimat (TPOXX®, SIGA), in a lethal intra-digital infection by ectromelia virus in mice. Importantly, a combined drug made from NV-387 and tecovirimat was more effective than either drug alone, indicating NV-387 “plays well” with tecovirimat and acts by a different mechanism.

  • Smallpox poses a significant biodefense threat. Ectromelia virus is a native virus of mice in the poxvirus family and is one of the key animal model viruses for developing smallpox therapeutics. Tecovirimat is an approved drug for treating smallpox infection based on the FDA “Animal Rule”, and is stockpiled by the US “Strategic National Stockpile”. It was mobilized during the recent monkeypox epidemic.
  • It is important to develop additional smallpox therapeutics that work well with tecovirimat and by themselves, since viruses pose the threat of drug escape by mutation; further, in a bio-terrorism scenario, a human-engineered smallpox virus resistant to existing drugs could be a potential threat.
NanoViricides rang the opening bell of the New York Stock Exchange on Aug. 13, 2014. In the front center (left to right) are Meeta Vyas, Anil Diwan and Dr. Eugene Seymour.

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa – Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu

SHELTON, CT / ACCESS Newswire / May 16, 2025 / NanoViricides, Inc.(NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025with the Securities and Exchange Commission (SEC) on Thursday, May 15, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057825001336/nnvc-20250331x10q.htm) .

NV-387 – Phase II Clinical Trial to Treat MPox Infection – Unmet Medical Need

We reported that we submitted requisite due diligence information to the National Ethics Committee of the Democratic Republic of Congo (DRC) including a draft report from the Phase I clinical trial for the safety and tolerability of oral formulations of NV-387, the summary information from our studies for treatment of lethal MPox infections in animal models, as well as summary information on the manufacturing.

The National Ethics Committee found that the provided information was sufficient to justify a Phase II clinical trial, and has cleared us to file a Phase II Clinical Trial Application for the Use of Oral NV-387 for the Treatment of MPox Disease Caused by the hMPXV virus, subsequent to the reporting period.

We also reported that we have commissioned manufacture of clinical trial quantities of NV-387 drug substance and the corresponding NV-387 oral gummies formulations drug products at our own cGMP compliant facility in Shelton, CT.

We are now preparing the Phase II Clinical Trial Application for NV-387 to combat MPOX for submission to the DRC regulatory agency.

There is no drug available for the treatment of MPox disease. The MPox Clade 1a/1b viruses have a substantially greater fatality rate than COVID, at 3-4%, and Clade 1b has been disproportionately affecting pediatric populations.

The MPox Disease which is caused by hMPXV Clade 1a/1b virus infection was initially declared a Public Health Emergency of International Concern (PHEIC) by the WHO in August 2024, a designation that has been continued to stay in effect in April 2025, due to the severity of the pandemic in WHO African Region.

Spillover cases of MPox Clade 1a/1b have occurred in several Eastern and Western countries already, raising the probability that the epidemic may spread more widely, although the current MPox virus is not as communicable as Coronaviruses or Measles virus.

MPox Clade 2 spilled over from Africa into the Western World in a small pandemic during 2022, and has become endemic with several cases occurring every year in many countries, driven primarily by sexual contact. MPox Clade 2 causes much less severe disease than the Clade 1a and 1b viruses.

MPox/Smallpox drug represents a billion dollar market globally, should an effective drug be developed, because of potential biosecurity implications.

NV-387 as Treatment for Measles Virus Infection – Unmet Medical Need

Upon finding significant rationale that NV-387 would be potentially highly effective against the Measles virus, we have initiated a program to evaluate NV-387 in a humanized animal model of Measles lethal infection.

The Measles outbreaks in the USA have continued to grow since January, 2025, and have crossed 1,000 confirmed cases as well as 3 deaths. Measles cases have been increasing year over year in the USA, especially after the COVID pandemic substantially resolved with the SARS-CoV-2 becoming an endemic virus. In Europe, over 35,000 cases of Measles have been reported in 2024 according to the European CDC.

A 95% vaccination coverage is required to eliminate Measles virus. This has become a practically impossible goal because of several factors, among them: (i) Vaccine Hesitancy as a rebound public response because of compulsion of COVID vaccine shots multiple times; (ii) Religious Vaccine Prohibitions in certain communities, including certain Jewish religious communities, Mennonites, and other conservative religious communities; (iii) Increasing immune function disability in the general population due to chronic diseases such as Diabetes, Obesity, Cardiac Issues, Autoimmune Diseases, Allergies, etc. wherein the person upon vaccination would not develop strong enough immunity and would become a carrier if infected; (iv) Vaccine Failure caused primarily by a variety of immune function disabilities.

The Measles vaccination rates across the world, and particularly in European countries and the USA have dipped well below 95% on average, and much lower in specific areas, and vaccine breakout cases i.e. Measles disease in vaccinated persons, have also increased substantially, as seen from the ECDC statistics [1] , [2] .

It is therefore essential to develop a drug to treat Measles in order to combat these outbreaks and achieve full control over the public health situation. There is no drug available for treatment of Measles.

We strongly expect that NV-387 would be effective against Measles. This is because NV-387 cured lethal RSV infection in an animal model. RSV and Measles both are paramyxoviruses, and both use HSPG as the Attachment Receptor, and then transfer to their respective Cognate Receptor that is needed for cell fusion. NV-387 was designed to present to the virus like a cell that displays HSPG-mimetic small chemical ligands on its surface, thereby providing the attachment-receptor-mimetic landing sites for the virus, capturing, engulfing, and destroying it. (HSPG = Heparan Sulfated Proteoglycans).

NV-387 as Treatment for Bird Flu, H5N1, H7N9 – Unmet Medical Need

We have previously found that NV-387 was substantially more effective than the existing stockpiled influenza virus treatments including Tamiflu (oseltamivir) and Xofluza (baloxavir) in lethal animal models of Influenza virus lung infection.

Given the extremely broad antiviral activity spectrum of NV-387, and knowing that the Highly Pathogenic Avian Influenza (HPAI) viruses such as H5N1 and H7N9 have polybasic sequences in their H-protein that bind to HSPG, we believe NV-387 would be effective against Bird Flu viruses.

Influenza viruses mutate rapidly, and also exchange their full genomic RNA segments with other co-infecting viruses (“Re-assortment”), or copy portions of a different genomic sequence into their own RNA (“Re-combination”). Thereby an Influenza virus can acquire new traits such as (i) rapid communicability from person-to-person, and (ii) readily escaping vaccines, antibodies, and the small chemical drugs such as oseltamivir and baloxavir.

NV-387, we believe, fulfills the unmet medical need for a pan-Influenza drug that the Influenza virus would not be able to escape, because the virus does not lose its ability bind to HSPG as Attachment Receptor and then to Sialic Acid Receptors leading to cell fusion and infection.

A severe version of H5N1 is widely circulating in the wild birds, and has caused sporadic losses of entire poultry farm houses. This, and a mild version of H5N1 have infected thousands of dairy herds in the USA. The H5N1 virus is only a few mutations away from becoming highly communicable from person to person, and if that comes to bear, we would be facing a pandemic possibly worse than COVID-19.

It is well established now that vaccines, antibodies, and small chemical drugs do not provide the ability to stall an outbreak let alone a pandemic caused by a highly variable virus such as a Coronavirus or an Influenza virus.

We believe NV-387 will be ready to fight any human outbreaks of H5N1 under emergency use protocols for investigational drugs.

Company Financials

We reported that, as of March 31, 2025, we had cash and cash equivalent current assets balance of approximately $2.73 Million. In addition, we reported approximately $6.98 Million in Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $1.20 Million.

The net cash utilized during the nine months ended March 31, 2025 was approximately $6.78 million. This included certain non-recurring expenditures including R&D expenditures in preparation for a Phase IIclinical trial application. We raised approximately $4.57 million net of commission and certain expenses in an At-the-Market offering (“ATM”) during the nine months ended March 31, 2025.

We have approximately $5.7 million (approximately $4.5 million net of current liabilities) available for cash operational expenses going forward including an available line of credit of $3 million provided by our founder and President Dr. Anil Diwan. As such, we reported that we do not have sufficient funding in hand to continue operations through February 14, 2026, for our planned objectives that include (i) a Phase II clinical trial of NV-387 for MPOX in Central Africa, (ii) a Phase II clinical trial of NV-387 for Viral Acute and Severe Acute Respiratory Infections (V-ARI and V-SARI), and (iii) Preparation and pre-IND filing for a Phase II clinical trial of NV-387 for RSV indication in the USA. We have access to the aforementioned ATM Equity Offering, and we believe we will have access to the equity markets to raise the funds necessary for our current objectives. We continue to re-prioritize our programs in line with available resources.

NV-387 – Phase I Clinical Trial Completed Successfully with No Reported Adverse Events

NV-387 has successfully completed a Phase Ia/Ib clinical trial in healthy subjects with all subjects discharged as of end of December, 2023. There were no adverse events reported. We are now awaiting a final report of this Phase I clinical trial.

NV-387 A Potentially Revolutionary Antiviral Drug that the Viruses are Unlikely to Escape

Our host-mimetic, direct-acting, broad-spectrum, antiviral agent. NV-387 was found to have activity that surpassed the activity of known agents in lethal virus infection animal model trials for COVID, RSV, Influenza, and Mpox/Smallpox.

In fact, we found that NV-387 treatment possibly completely cured the lethal RSV infection in mice, based on indefinite survival of the animals with no lung pathology. There is currently no treatment for RSV infection. In particular, pediatric RSV infection treatment is an unmet medical need that we believe is of critical importance. Pediatric RSV treatment itself is expected to be a multi-billion-dollar market in the USA alone.

NV-387 treatment was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche).

Additionally, NV-387 also demonstrated activity against lethal poxvirus infection animal models that was on par with or superior to the approved drug tecovirimat (TPOXX®, SIGA).

NV-387 acts by a mechanism that is significantly different compared to the tested existing antiviral agents for COVID, Influenza and Poxviruses.

This demonstrated broad-spectrum activity of NV-387 against widely varying viruses is because NV-387 is designed to attack the virus particle by mimicking sulfated proteoglycan (S-PG) feature, and all of these viruses are known to utilize heparan sulfate proteoglycans for gaining cell entry.

Further, for all of these tested viruses, even as the virus genome changes in the field, NV-387 is expected to continue to be effective, and the virus would be highly unlikely to escape NV-387. This is because despite all of the genomic changes, the virus continues to use HSPG, as is well known. Thus NV-387 solves the greatest problem in antiviral countermeasures; the problem of virus escape. Viruses are known to escape all of the current antiviral tools that include vaccines, antibodies, and small chemical drugs.

Thus we anticipate that NV-387 would revolutionize the treatment of viral infections reminiscent of how penicillin revolutionized the treatment of bacterial infections.

NV-387 Regulatory Strategy

In the ensuing year, we plan on advancing NV-387 into Phase II clinical trials. In addition to the Phase II clinical trial to assess effectiveness of NV-387 in treating MPox infections, we are also planning to advance NV-387 into a Phase II clinical trial for treatment of Viral Acute Respiratory Infections (V-ARI), and Viral Severe Acute Respiratory Infections (V-SARI). This clinical trial is expected to provide information on NV-387 effectiveness in treating Influenza viruses, Coronaviruses (including SARS-CoV-2/COVID) as well as RSV.

Thereafter we are planning a regulatory program for advancing NV-387 as the treatment of pediatric RSV infection.

We plan on advancing the regulatory processes for NV-387 registration for other indications including Influenza and COVID via partnerships and non-dilutive funding.

As we meet the milestones, we believe we will be able to raise financing for further regulatory activities for NV-387 registration via non-dilutive grant funding, partnership revenues, as well as equity

bindingimage

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides’ Dr. Diwan

PUBLISHED

JUN 18, 2025 6:30AM EDT

SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), asserts that with new rising variants of COVID and Bird Flu, the single broad-spectrum antiviral drug NV-387 is well-positioned to support preparedness efforts and to combat potential pandemics.

Nimbus, a new COVID variant, officially NB1.8.1, is displacing the LP8.1 variant that was dominant until a few weeks ago in the USA(https://www.today.com/health/coronavirus/new-covid-variant-nb181-nimbus-symptoms-rcna212304).

Nimbus has been rising globally since Spring according to WHO(https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf).

Nimbus causes “razor-sharp” sore throat in some individuals, which is extremely painful and lingering for some time, in addition to the usual COVID symptoms.

Nimbus is more resistant to antibodies generated from previous vaccines, although prior vaccination or natural COVID infection is expected to still be protective in terms reduced severity compared to without such immunity according to CDC.

Nimbus is likely to be more transmissible than the previous variants. It belongs to the JN.1 subfamily of the Omicron family of SARS-CoV-2 virus.

Recently, the Influenza A H5N1 virus from a dairy worker in Michiganwas found to be capable of airborne transmission in a ferret animal model [1] (https://www.freep.com/story/news/health/2025/06/05/h5n1-bird-flu-michigan-dairy-farm-airborne-spread-cdc-study/84046550007/). This genotype B3.13 (clade clade 2.3.4.4b) virus in dairy cattle causes moderate severity disease in humans. In contrast, a highly pathogenic genotype D1.1 that is circulating in birds birds has led to one critical month-long illness in Canada and one death in the US signifying the potential for high morbidity and mortality from this genotype if it spreads in humans.

Additionally, a new genotype of H5N1 in Cambodia has caused four fatalities and fifth severe infection as of today (https://www.cidrap.umn.edu/avian-influenza-bird-flu/h5n1-avian-flu-infects-fifth-patient-cambodia).

NV-387, the broad-spectrum antiviral drug is expected to be effective against all of these bird flu viruses. NV-387 was found to be substantially superior to Tamiflu® (Roche, Oseltamivir), Rapivab® (Biocryst, Peramivir), as well as Xofluza (Shionogi/Roche, baloxavir) in lethal lung infection animal model of Influenza infection. All three of these existing anti-influenza drugs are known to be escaped by Influenza viruses by single point mutations in H or PB2 genes.

NV-387 was found to be substantially superior to the approved drug Remdesivir in a lethal coronavirus lung infection animal model for SARS-CoV-2.

Thus the single drug NV-387 alone can combat H5N1, Influenza as well as COVID infections.

NV-387 has completed Phase I clinical trial in healthy human subjects with no reported adverse events.

COVID as well as Influenza viruses readily escape vaccines, antibodies as they change in the field during an epidemic wave. They are also likely to escape small molecule drugs by such changes.

NV-387 takes advantage of the invariant features that these viruses use for causing infection, by mimicking heparan sulfate-like structures. No matter how much these viruses change in the field, they continue to use the heparan sulfate attachment receptors in order to cause infection. Thus it is practically impossible that the viruses may be able escape NV-387 without losing their ability infect and transmit across humans, the Company believes.

NV-387 is orally available, formulated as oral gummies that dissolve in the mouth, thus avoiding issues of inability to swallow which occurs related to sore throat, old age, as well as in young children.

NV-387, as a treatment, is designed to help actually patients with disease recover rapidly, thus limiting the viral spread as well as providing for natural infection-based immunity in the recovered patient.

“NV-387 is thus the best current choice available for a highly cost-effective pandemic preparedness development,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “We have US-based cGMP manufacturing capabilities already set up as well.”

Of note, natural immunity, as induced by recovery from infection, is known to be superior to immunity from subunit and mRNA vaccines. One of the important reasons is that in natural infection, the immune system is subjected to all possible antigens from the entire virus, unlike just the selected antigens or antigen fragments that are present in subunit or mRNA vaccines.

Also, NV-387 can be manufactured in the USA and stockpiled readily at room temperature or refrigeration (for longer periods of time).

Unlike NV-387, vaccines or antibodies would require to be created after the virus takes hold, and they would suffer substantial loss of effectiveness within months after deployment due to changes in the virus. Additionally, vaccines require a cold chain handling. Vaccines also need to be administered to a large proportion of healthy population. There are significant logistical problems with vaccines. There is also the issue of vaccine reluctance, which is a personal choice, as it should be in a free country like the USA.

The broad-spectrum antiviral drug NV-387 was developed specifically to overcome all of these problems. In case of further spread of a severe COVID variant and also a Bird Flu variant in human populations, it will be possible to move NV-387 rapidly into Phase II clinical trial for these diseases, and then prepare for deployment early in the potential pandemic, curtailing its spread.

About NanoViricides

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”) today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic of Congo (DRC). With this CNES approval, the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is cleared for further regulatory filing of a complete Clinical Trial Application (“CTA”).

“We are now fully engaged in completing the detailed CTA for the Phase II human clinical trial of NV-387 for the treatment of MPOX disease (hMPXV infection) for submission to the DRC Regulatory Agency, namely MSP,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company.

The Company previously announced in January, 2025 that it has engaged a CRO for conducting a Phase II clinical trial to evaluate the safety and effectiveness of NV-387 for the treatment of MPox in the African Region.

Subsequently, the CRO has engaged the Medical Hospital at the University of Kinshasa as the clinical trial site (the “Site”) for the Phase II clinical trial.

Thereafter, the Company, the CRO, and the Principal Investigator at the Site have developed a package of information comprising synopses of the clinical trial protocol, and required background information on the novel drug NV-387, including a draft summary report of the Phase I human clinical trial, prior non-clinical data, as well as summary of the animal model effectiveness and safety of NV-387 for the treatment of lethal MPox infection providing rationale for the use of the novel broad-spectrum antiviral drug NV-387 for the treatment of hMPXV viral infection and the MPox disease caused by the infection.

This summary package was submitted to the National Regulatory Agency’s Ethics Committee CNES for a first review towards approval to proceed to the preparation and submission of the detailed CTA to the National Regulatory Agency, namely MSP of DRC.

The approval that we have now received from CNES clears the path for the perfected CTA filing to the MSP for approval and start of the clinical trial.

There is no drug available for the treatment of hMPXV infection that causes the MPox disease. A clinical trial of tecovirimat (TPOXX®, SIGA) failed to demonstrate any effectiveness over placebo, as per a NIH press release on August 15, 2024.

“NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases,” said Anil R. Diwan, Ph.D., adding “NV-387 is designed to mimic human cells to trap and destroy the virus. This single drug can target over 90-95% of human pathogenic viruses due to this biomimicry, which is reminiscent of the antibiotic penicillin that targets a large number of human pathogenic bacteria.”

NV-387 was found to be highly effective in increasing survival in lethal animal models of influenza virus, surpassing existing drugs Tamiflu®, Rapivab® and Xofluza® by a large margin.

NV-387 led to a complete cure of lethal RSV lung infection in an animal model study. There is no approved drug for RSV treatment.

NV-387 was found to be highly effective in increasing survival in lethal animal models of Coronavirus infection (a stand-in model for SARS-CoV-2 infection), surpassing existing drug remdesivir by a large margin.

NV-387 was found to possess strong antiviral activity against an orthopoxvirus in an animal model that is considered an important model to establish potential effectiveness against MPox and Smallpox viruses, as all of these viruses belong to the same family of orthopoxviruses.

In fact, NV-387 effectiveness matched the effectiveness of the small chemical drug tecovirimat in two different models of infection, one was direct skin infection, and the other was a direct lung infection, by the virus.

Escape of virus from tecovirimat can occur by a single point mutation in a viral protein called VP-37.

Vaccines, antibodies, and small chemical drugs such as tecovirimat for MPox/Smallpox, or oseltamivir (Tamiflu®), baloxavir (Xofluza®) for Influenza are readily escaped by viruses simply by introduction of small changes that viruses undergo when they are faced with these challenges in the field.

In contrast, escape of virus from NV-387 is highly unlikely because no matter how much the virus changes in the field, it continues to use sulfated proteoglycans such as HSPG as “attachment receptor” in order to cause cell infection. NV-387 mimics the sulfated proteoglycan signature feature that the viruses require.

MPox disease, caused by the human MPox virus (hMPXV) has been causing a regional pandemic encompassing several countries in the WHO African Region that includs the Democratic Republic of Congo (DRC), Uganda, and other countries. It led to the WHOdeclaring a Public Health Emergency of International Concern (“PHEIC”) on August 14, 2024. Since then, the PHEIC status declaration has been extended twice, most recently in March, 2025. The Mpox epidemic has continued to spread in the DRC, Uganda, and neighboring countries and the number of new weekly cases is still increasing in the WHO African Region.

NV-387 is a host-mimetic drug that “looks like a cell” to the virus, displaying numerous ligands that mimic the sulfated proteoglycan, enticing the virus to bind to and become engulfed by the NV-387 dynamic shape-shifting polymeric micelle.

Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug undergoes regulatory development for approval for use in humans.

New viruses and existing viruses acquiring greater pathology and infectivity are bound to keep appearing in time. To combat such threats, we need to develop broad-spectrum drug arsenal that the viruses cannot escape. Vaccines and antibodies simply will not do, and their limitations have become clearly evident during the COVID-19 pandemic.

NEWS


NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

6 days ago

Measles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 21, 2025

WHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jul 16, 2025

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

Jul 14, 2025

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

Jul 1, 2025

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides’ Dr. Diwan

Jun 18, 2025

NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 28, 2025

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides’ Dr. Diwan

May 22, 2025

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa – Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu


Measles Cases Are Increasing Globally; MPox Continues to Be a Threat – Broad-Spectrum Antiviral Drug Could Be the Solution

May 14, 2025

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

May 8, 2025

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

May 5, 2025

Measles is Likely to Become Endemic – NanoViricides Is Testing a Drug to Combat It

Apr 29, 2025

Measles Outbreak Expands Begging for a Drug to Treat the Infection – NanoViricides Declares it is Ready to Fight the Outbreak

Apr 14, 2025

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 11, 2025

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Mar 4, 2025

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 19, 2025

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Feb 11, 2025

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 29, 2025

‍

MANAGEMENT

‍

Anil R. Diwan, PhDExecutive Chairman, President

Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.

Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.

He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.

Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)

interim Chief Financial Officer

Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.

Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.

NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.

‍

Randall W. Barton, PhD.Chief Scientific Officer – Consulting

Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.

Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.  

Jayant Tatake, PhD.

Vice President, R&D

Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.

Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND TWENTY FIVE USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

ATLX

***Sponsored by Sideways Frequency, LLC

ATLX

‍

Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production

CHECK OUT THE INVESTOR PRESENTATION HERE ‍

_________________________

Hello Everyone,

We are bringing back a company that we have asked you to research a hand full of times in 2025.

The last time we looked at it was late May when it was around 3.80. Less than 2 weeks later it hit 5.15.

It is back right around 4.50 after a double digit pull back today.

We think that right now is another good time to research ATLX.

Focused on moving from exploration to profitability; Atlas Lithium Corporation (NASDAQ: ATLX) is a U.S.-based mineral exploration company with the largest size and breadth of exploration projects for strategic minerals in Brazil, a premier mineral jurisdiction.

ATLX intends to be a leader in the provisioning of minerals essential to the transformation of the global economy from fossil fuels to electrification, a process which is expected to take decades.

The company’s properties encompass approximately 539 km2 for lithium, as well as mineral rights for nickel, rare earths, titanium and graphite. Atlas Lithium also owns 32% of Atlas Critical Minerals Corporation.

Over the last several years, Atlas Lithium has assembled Brazil’s largest portfolio of lithium mineral rights among publicly listed companies.

ATLX holds three key projects that span the major lithium-mineralized zones in LV:

  1. The Neves Project in southern LV, Atlas Lithium’s flagship development, which has recently been permitted and is advancing towards production;

  2. The Salinas Project in northern LV, spanning 2,070 acres with natural spodumene outcrops, and is located 4.7 miles from Latin Resources Ltd., and with potential for spodumene deposits;

  3. The Clear Project in central LV, which encompasses 470 acres, is situated 3.8 miles from Sigma Lithium’s (NASDAQ: SGML) Grota do Cirilo mine. There is also potential for spodumene deposits. Sigma Lithium has a market cap of roughly $1.2B! (Note: ATLX’s lithium processing manager James Schloffer had a key role at Sigma!)

Atlas Lithium’s Critical Minerals Subsidiary Reports Strong Rare Earths, Titanium, and Graphite Results

Atlas Critical Minerals reports high-grade, near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂; achieves 96.6% graphite concentrate

Boca Raton, Florida–(Newsfile Corp. – July 24, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or the “Company”), a leading lithium exploration and development company, today announced strong results from its 30.1%-owned subsidiary, Atlas Critical Minerals Corporation (OTCQB: JUPGF). The subsidiary has recently reported near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂, alongside graphite concentrate results of up to 96.6%. Atlas Critical Minerals owns over 575,000+ acres of mineral rights for rare earths, titanium, graphite, uranium, copper, and nickel. Brazil, where the subsidiary operates, hosts significant rare earth deposits and holds the world’s second-largest graphite reserves.

Alto Paranaíba Rare Earths and Titanium Project Demonstrates High Potential

Atlas Critical Minerals’ Alto Paranaíba rare earths and titanium project in Minas Gerais, located in a proven rare earths region, is divided into three exploration blocks for operational efficiency as shown in Figure 1.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6706/259897_14822f5ff4efe99a_002.jpg

Figure 1: Alto Paranaíba Project Exploration Blocks

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6706/259897_14822f5ff4efe99a_002full.jpg

Atlas Critical Minerals’ 770 surface samples yielded consistently attractive grades, including a sample with 28,870 ppm total rare earth oxides (TREO) and another containing 23.2% titanium dioxide (TiO₂). Highlight sampling results from Block 3 South are presented in Figure 2.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6706/259897_14822f5ff4efe99a_003.jpg

Figure 2: High-Grade Surface Sampling Results

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6706/259897_14822f5ff4efe99a_003full.jpg

Graphite Project Delivers Outstanding Initial Results

Atlas Critical Minerals’ Minas Gerais graphite project achieved strong metallurgical test results, with conventional flotation techniques producing graphite concentrates grading up to 96.6% total graphite carbon. Exploration samples showed graphite carbon grades up to 15.42%.

Strategic Importance

The strategic importance of securing robust critical minerals supply chains was recently underscored by the U.S. Department of Defense’s $400 million investment in MP Materials, making it the largest shareholder in the U.S. rare earth miner.

Atlas Lithium’s strategic stake in Atlas Critical Minerals provides shareholders with direct exposure to the broader critical minerals sector and strengthens the Company’s position within global supply chains for materials vital to energy transition and national security.

“Our focus remains on advancing our flagship Neves lithium project toward production, while our significant stake in Atlas Critical Minerals allows our shareholders to also benefit from exposure to a broader range of critical minerals at a time of heightened geopolitical importance,” said Marc Fogassa, Chief Executive Officer and Chairman of Atlas Lithium. “The initial results from Atlas Critical Minerals’ rare earths, titanium, and graphite programs are highly encouraging and underscore the strong potential of these assets.”

Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production

South Africa plant

Boca Raton, Florida–(Newsfile Corp. – March 10, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium development company, announces the successful arrival of its modular Dense Media Separation (DMS) lithium processing plant at the Port of Santos, Brazil. This pivotal achievement underscores the Company’s progress toward becoming a key lithium producer in Brazil’s emerging Lithium Valley.

The components of Atlas Lithium’s lithium processing plant were carried by the cargo vessel Irene’s Wisdom (IMO: 9953391) which arrived at the Port of Santos on March 7, 2025, delivering 141 containers and 10 bulk components. Fully owned and paid for by Atlas Lithium, this newly manufactured facility departed from the Port of Durban, South Africa, on February 2, 2025, following months of careful planning and preparation. Two additional containers, containing spare parts, are scheduled to arrive in the near future.

“This marks a transformative milestone for Atlas Lithium as we advance toward becoming a global supplier in the lithium market,” said Marc Fogassa, Chairman and CEO of Atlas Lithium. “With operational permits secured and our modern lithium processing facility now in Brazil, we have overcome two of the most significant hurdles on our journey to production.”

Cutting-Edge Modular Plant Design

Atlas Lithium’s lithium processing plant incorporates advanced design elements and sustainable technology that set a new benchmark for lithium processing:

  • Compact, Modular Design: Allows streamlined transportation, installation, and commissioning, reducing time to production.
  • Reduced Environmental Footprint: Optimized physical layout minimizes environmental impact while maintaining high operational efficiency.
  • Advanced Water Conservation: Internal recycling systems with lower water consumption compared to traditional plants.
  • Sustainable Tailings Management: Dry-stacking technology eliminates the need for tailings dams, promoting greater environmental sustainability.

Strategic Progress Toward Production

The Neves Project, Atlas Lithium’s flagship operation, received its operational permit from the state of Minas Gerais in October 2024. The project is positioned to initially produce up to 150,000 tonnes per year of battery-grade spodumene concentrate, a critical raw material for lithium-ion batteries.

Atlas Lithium’s operations will benefit from Brazil’s Lithium Valley’s strategic advantages, including expected lower production costs as compared to suppliers from Australia and other regions.

Atlas Lithium Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure

Boca Raton, Florida–(Newsfile Corp. – March 5, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium exploration and development company, is pleased to highlight its current 32.2% stake in Atlas Critical Minerals Corporation. This ownership positions Atlas Lithium at the forefront of Brazil’s critical minerals sector, providing exposure to rare earth elements, titanium, graphite, uranium, and other sought-after minerals.

“Global demand for critical minerals has never been more urgent,” said Marc Fogassa, CEO and Chairman of Atlas Lithium. “Recent geopolitical developments have underscored the vital importance of critical minerals for economic and national security. Atlas Lithium is strategically positioned to play a key role in this increasingly important sector.”

Rare Earths: Essential for Defense, Energy, and High-Tech Applications

Rare earth elements are indispensable components in manufacturing permanent magnets used in electric vehicle (EV) motors, wind turbines, and defense systems. With Chinacurrently controlling over 60% of global rare earth mining and 85% of refining capacity, recent export restrictions have underscored the need for alternative supply sources.

Atlas Critical Minerals’ extensive rare earth portfolio spans approximately 54,000 hectares (~133,000 acres) across 33 mineral rights in the states of Goiás and Minas Gerais in Brazil. These areas have demonstrated promising mineralization, with soil samples revealing rare earth oxide (TREO) concentrations as high as 15,000 ppm and titanium dioxide concentrations up to 20%.

Graphite: A Cornerstone of Battery Technology

Graphite is a critical component for lithium-ion batteries, which power electric vehicles and renewable energy storage systems. As global EV adoption accelerates, demand for natural graphite has surged, making the development of new sources outside of traditional suppliers like China a strategic imperative. Atlas Critical Minerals is actively evaluating areas in Brazil with known graphite formations, with the goal of contributing to the global supply of this essential material.

Uranium: Fueling the Energy Transition

Uranium is experiencing renewed global demand as nations prioritize energy security, geopolitical stability, and decarbonization. With nuclear power offering a reliable, low-carbon energy source, uranium has become integral to the energy transition. Atlas Critical Minerals is focused in certain areas in Brazil with promising geological characteristics for uranium. In Brazil, uranium is strictly regulated and exploration requires special permitting, which is not guaranteed. Nevertheless, this sector is expected to continue to grow substantially as Brazil activates its third nuclear reactor for electricity generation and as global demand continues to rise.

A Diversified Strategy for a Changing World

Atlas Lithium’s ownership stake in Atlas Critical Minerals strategically complements its flagship Neves Project in Brazil’s Lithium Valley. This diversified approach provides shareholders with exposure to multiple critical minerals essential for the global energy transition and advanced manufacturing sectors.

“In today’s environment of persistent geopolitical tensions, the need for reliable, diversified critical mineral supply chains has never been clearer,” added Fogassa. “While our immediate focus is to bring our lithium production online and generate profits, Atlas Lithium’s long-term strategy is to establish itself as a leader in the global critical minerals space.”

Strategic Partnership with Global Industrial Giant

In a transformative development, Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries. In March 2024, Mitsui demonstrated its confidence in Atlas Lithium’s potential by making a substantial US$30 million strategic investment at a 10% premium to market price. The partnership includes a significant offtake agreement lithium concentrate from Atlas Lithium’s Neves Project. Notably, Mitsui’s largest shareholder is Warren Buffett’s Berkshire Hathaway, adding another layer of institutional validation to Atlas Lithium’s business model.

Mine

‍

Within the global lithium industry, Brazil’s LV has emerged as a premier hard-rock lithium jurisdiction.

Brazil’s advantages include year-round mining operations, lower labor costs, and a supportive government. The country’s lithium industry outperforms Australian producers on costs; Pilbara Mineral’s US$370M acquisition of a Brazilian lithium explorer in August 2024 highlights the region’s importance.


“Investments in lithium production in Minas Gerais are projected to range from $3.9 billion to $5.8 billion by 2030,” according to João Paulo Braga, CEO of the state investment promotion agency, Invest Minas.

Few countries besides Brazil have such an advantageous position to attract investment, as other Latin American nations face uncertainties and political risks.

ATLX’s Minas Gerais Lithium Project is its largest endeavor and consists of 85 mineral rights totaling approximately 468 km2 which include seven main clusters of prospective mineralization: Neves (currently being explored by drilling campaign and referred to as the “Neves Project”), Coronel Murta, Eastern Properties, Itinga, Salinas, Santa Clara, and Tesouras.

Several of the company’s mineral rights are located adjacent to or near mineral rights that belong to a large publicly traded competitor company which has demonstrated through extensive drilling the presence of lithium deposits totaling over 100 million tons, according to its publicly available filings!

This is a Highly Attractive Location:

◼ Resource Potential to Support Large Scale Operations
✓ The Brazilian Geological Service (CPRM) suggested that the region has at least 45 lithium deposits
✓ Adjacent to operational lithium mines in the region such as Sigma Lithium and CBL

◼ Licensing Fast Track to Speed up Project Execution – Atlas with Permits in Place
✓ Minas Gerais government created a fast-track process, under the InvestMinas Program, to facilitate project development and allow for licensing to be issued quickly
✓ Mining friendly jurisdiction: 300+ operating mines in the state of Minas Gerais

◼ Favorable Infrastructure
✓ Access to abundant renewable & clean energy sources and highway roads directly connected to intercontinental ports to supply main markets

Map

Recent exploration activities at both the company’s Salinas and the Clear Projects have yielded significant progress, and such development bodes well for ATLX’s strategy of securing as many high-quality deposit areas within LV as feasible.

A Big Neighbor

Atlas Lithium’s strategic holdings of 85 mineral rights across 468 km2 in Minas Gerais position it as the emerging force in Brazil’s Lithium Valley, with several properties adjacent to Sigma Lithium Corporation, the region’s established producer. Sigma’s current market capitalization of approximately $1.2 billion—approximately twelve times that of Atlas Lithium—demonstrates the extraordinary value potential in the region. As Atlas Lithium follows a similar development path in the same proven lithium district the company represents a compelling growth opportunity at its current market valuation. The success of Sigma Lithium in establishing large-scale lithium operations provides a clear blueprint for Atlas Lithium’s development trajectory in this world-class mining jurisdiction.

‍

NEWS


Atlas Lithium’s Critical Minerals Subsidiary Reports Strong Rare Earths, Titanium, and Graphite Results

4 days ago

Brazil Lithium & Critical Minerals Summit 2025 Launches with Record Participation and Global Momentum

Jun 5, 2025

Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production

Mar 10, 2025

Atlas Lithium Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure

Mar 5, 2025

Atlas Lithium to Present at Fastmarkets Battery Raw Materials Shanghai 2025 Conference

Feb 10, 2025

Atlas Lithium’s Plant Is Now En Route to Brazil – Marking Major Milestone Towards Production

Feb 3, 2025

Atlas Lithium’s Processing Plant Prepares for Shipment to Brazil

Jan 21, 2025

Atlas Lithium Accelerates Production Readiness with Key Executive Appointments

Dec 30, 2024

Atlas Lithium Outlines Regional Growth Strategy

Nov 25, 2024

Atlas Lithium’s Neves Project Is Now Permitted

Oct 28, 2024

‍

MANAGEMENT

Marc Fogassa

Chairman & Chief Executive Officer

Marc Fogassa has been a director and our Chairman and Chief Executive Officer since 2012. He has extensive experience in venture capital and public company chief executive management. He has served on boards of directors of multiple private companies in various industries and has been invited to speak about investment issues, particularly as related to Brazil. Mr. Fogassa double majored at the Massachusetts Institute of Technology (M.I.T.), graduating with two Bachelor of Science degrees in 1990. He later graduated from the Harvard Medical School with a Doctor of Medicine degree in 1995 and also from the Harvard Business School with a Master of Business Administration degree in 1999 with Second-Year Honors. At Harvard Business School, he was Co-President of the Venture Capital and Private Equity Club. Mr. Fogassa was born in Brazil and is fluent in Portuguese and English. Mr. Fogassa is also the Chairman and Chief Executive Officer of Jupiter Gold Corporation and Chairman and Chief Executive Officer of Apollo Resources Corporation, two companies in which we own equity positions.

Tiago Miranda

CFO & Treasurer

Tiago Miranda is our Chief Financial Officer, Principal Accounting Officer, and Treasurer. From February 2024 until July 2024, Mr. Miranda was the Chief Financial Officer of Apollo Resources Corporation, a private company and a subsidiary of Atlas Lithium. In such capacity, Mr. Miranda managed all of Apollo Resources’ financial and administrative related processes, including treasury, accounting, tax, and financial planning and budgeting.

Previously, from May 2020 to December 2023, Mr. Miranda was the senior financial officer for the Brazilian operations of Horizonte Minerals Plc., a British publicly listed company with two nickel projects in Brazil. During his tenure, he successfully contributed to securing project financing of US$713 million for a ferronickel project and an additional $300 million Brazilian real credit facility with Banco da Amazônia. Between November 2019 to April 2020, Mr. Miranda held the position of Financial Controller for the Brazilian operations at Equinox Gold, a Canadian publicly listed gold producer.

From March 2008 to October 2019, Mr. Miranda served as the Controller of Ferrous Resources Ltd., an iron producer partially owned by Icahn Enterprises, a NYSE-listed company. He actively contributed to the development of company projects from exploration through construction and operation and was also heavily involved in Ferrous Resources’ US$550 million sale to Vale S/A, the largest Brazilian mining company.

From September 2005 to March 2008, Mr. Miranda was an auditor with Deloitte Touche Tohmatsu in Brazil. He has an undergraduate degree in Business Administration and Accounting, and a Master of Business Administration, both from IBMEC in Brazil. Mr. Miranda is fluent in Portuguese and English.

Eduardo Queiroz

Project Management Officer (PMO) & Vice President of Engineering

Eduardo Queiroz has served as Project Management Officer and Vice President of Engineering at Atlas Lithium since December 2024. He brings over 20 years of expertise in managing large-scale and complex mining projects, most recently as General Manager of Planning and Management at Bamin, a unit of Eurasian Resources Group. During his tenure at Bamin, he successfully led the strategic planning of several projects exceeding US$3 billion in value, including an integrated iron ore mining project that encompassed mining operations, processing plant, railway, and ocean port facilities.

Mr. Queiroz’s comprehensive experience includes engineering oversight, environmental compliance, risk management, and the implementation of cost-efficient operational strategies. His expertise in project implementation and management of Brazilian mining projects makes him instrumental in driving Atlas Lithium’s Neves Project toward revenue generation. He holds an MBA in Project Management from Fundação Getúlio Vargas and a degree in Civil Engineering from the Universidade Federal de Ouro Preto.

Igor Tkachenko

Vice President, Corporate Strategy

Igor Tkachenko has been our Vice President of Corporate Strategy since 2023. Igor Tkachenko, a Ukrainian-American and a US-trained physician, has served as a strategic advisor to us since 2021, lending his leadership talents and private sector experience to further the company’s mission to become a leading hard-rock lithium provider for the green energy transition. In 2022, Mr. Tkachenko began consulting for us as our Director of Strategic Development, overseeing the rapid expansion of our investor relations efforts. He participated in the design and execution of our organizational growth strategy that led to our successful up-listing to Nasdaq in January 2023. On the heels of this major milestone, Mr. Tkachenko transitioned from his academic role as a Clinical Assistant Professor to take on an executive position at Atlas Lithium and began serving as our Vice President of Corporate Strategy in 2023. His education includes a Bachelor of Science (Summa Cum Laude) and a Doctor of Medicine degrees.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND SEVEN HUNDRED TWENTY FIVE USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY ATLX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

SER

***Sponsored by LFG Equities Corp

AgeX Therapeutics, Inc. Logo

‍

Check Out the Investor Presentation Here

‍_________________________

Hello Everyone,

July has been an incredible month so far as we look to close it out this week with some names that you are going to want on your radar heading into August.

For tomorrow we have something brand new that I have never seen anyone feature before. This one is virtually undiscovered, which is a GREAT catalyst because of the size of the float, which is just over 3 million according to Finviz.

Pull up SER right away.

This NYSE AMEX company is sitting in it’s newly established trading zone and has held onto a big portion of some of it’s recent move.

This one has an interesting story behind it. The founders already did it once. This company was founded in 2007 and was largely funded by the founders and certain investors who followed the team to Serina after the successful exit (via acquisition by Nektar Therapeutics) of the founding team’s prior company, Shearwater Polymers.

At Shearwater, Serina co-founders Dr. Milton Harris and Dr. Michael Bentley developed the first-generation of “PEGylated” drugs. PEG (polyethylene glycol) technology became the standard for delivery of protein drugs and has enabled 30 FDA approved products that have since generated over $140B in cumulative sales. Serina was founded to engineer a next generation polymer therapeutic (our POZ PlatformTM) to address the limitations of PEG and other biocompatible polymer technologies — enabling new treatment paradigms for patients suffering from some of the world’s most challenging diseases.

You can see that this one made a significant move to the upside on underwhelming interest. Based on what we have seen we think that SER has the capability to move under the right circumstances. You really want to take a good look at this one. They have been releasing a ton of news this year and the company looks to be heading in the right direction.

Serina is in the process of developing proprietary drugs to treat neurological diseases. Their lead product candidate, SER-252 for advanced Parkinsons Disease, is anticipated to enter clinical trials in 2025. Their current discovery and development work includes a focus on unlocking the potential of cannabinoids and other molecules across a range of CNS indications and beyond. Their POZ platform partners are at the forefront in advancing novel RNA medicines in vaccine immunology, cancer immunoRX, and gene therapy.

Their proprietary POZ platform technology has been designed for programmable, targeted delivery of a broad range of small molecules. The technology has been clinically demonstrated to safely enable continuous drug delivery via a once weekly subcutaneous injection. The POZ platform is customizable, versatile and can be Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).

The technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.

Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.

About SER-252 (POZ-apomorphine)

SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. Serina plans to advance SER 252 to clinical testing in 2025.

dosed via IV, SC or IM routes to address a broad range of clinical indications.

Our proprietary POZ platform is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”.

POZ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. The technology is optimized for small molecules and can also be applied to proteins, aptamers and other classes of molecules.

‍

Their largest shareholder, Juvenescence Ltd., just secured $150 million in Series B financing led by M42, a global tech-enables health company headquartered in Abu Dhabi.

This significant investment and accompanying strategic alliance will accelerate Juvenescence’s mission to develop innovative therapies targeting age-related diseases and extending healthspan. As part of this partnership, Juvenescence and M42 will launch a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with cutting-edge data and clinical infrastructure to speed the development of novel therapeutics.

Juvenescence has been a critical partner to Serina, providing strategic guidance and capital that has helped them advance their POZ Platform™ into the clinic.

NEWS‍

‍
Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 10, 2025

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jul 1, 2025

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 23, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 17, 2025

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event “Is the Beaten Down Biotech Sector the Smartest Bet in Today’s Volatile Market?”

Jun 9, 2025

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 22, 2025

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 14, 2025

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 8, 2025

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 29, 2025‍

‍
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 15, 2025

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson’s Disease

Apr 8, 2025

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Apr 7, 2025

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Mar 24, 2025

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 12, 2025

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson’s Disease Patients

Feb 3, 2025

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 15, 2025

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Jan 14, 2025

Serina Therapeutics to Present at Tribe Public’s Webinar Event “Enabling Continuous Drug Delivery for Parkinson’s Disease & Beyond” on Wednesday, December 18, 2024

Dec 16, 2024

MANAGEMENT

Simba-Gill

‍

Simba Gill, Ph.D.
Executive Chairman

Simba has a wealth of biotech and pharma experience in building companies and transformative platforms as well as developing products, having served in key executive roles at Maxygen, Systemix, Boehringer Mannheim and Celltech over his thirty-year career.  He has served as a partner and advisor at Flagship Pioneering where he was the founding CEO of Evelo Biosciences and as a Venture Partner at TPG where he was Founder CEO of Moksh8 Pharmaceuticals. Simba is currently a board member at Foghorn Therapeutics (NASDAQ – FHTX) and Sensorium Therapeutics. He earned his MBA at INSEAD and received his Ph.D. from King’s College, London.

Steve Ledger
Steve Ledger

CEO and Director

Steve has served as CEO since March 2024 and CFO from March 2022 to March 2024. He has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early-stage companies. He is a General Partner of Form & Fiction Ventures (FFV), a venture studio that launches and invests in startup and seed stage companies focused on socially responsible initiatives. He has served in investment management roles at Caldwell Sutter Capital, Tamalpais Partners, SF Sentry Securities, Kayne Anderson, and Fidelity Investments. Mr. Ledger received a B.A. in Economics from the University of Connecticut.

Randall
Randall Moreadith, M.D., Ph.D.
Chief Development Officer

Randall has served as Serina’s CDO since March 2024. He served as Serina’s President, CEO, and member of Serina’s board of directors from September 2010 to March 2024. Prior to Serina, Randall served in executive leadership roles including CDO at Nektar Therapeutics, CMO of Cardium Therapeutics, CMO at Renovis, and President / co-Founder of ThromboGenics (now Oxurion). Dr. Moreadith received his M.D. from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. Following his Fellowship in Cardiology at Duke University, he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith received his Ph.D. from Johns Hopkins University.

Greg Curban
‍
Greg Curhan
CFO

Greg joined Serina as CFO in August 2024. He has over 35 years of operational, financial, capital markets and strategic advisory experience in various sectors including Investment Banking and Medical Device/Life Sciences. Greg has been a Partner at FLG Partners since 2020. Also since 2020, Greg has served as the CFO for Curevo Vaccines, a private biotech company focused on infectious disease immunology. As CFO, Greg has managed Finance, Legal, HR, and Investor Relations functions for Public and Private companies. He has raised equity and debt capital for both private and public companies, completed numerous successful IPOs, and executed M&A transactions, both acquiring and divesting companies. He has also served in CEO, President and Board of Director capacities. Greg earned a BA degree in Economics from Dartmouth College.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND TWENTY FIVE USD BY LFG EQUITIES CORP FOR A ONE DAY SER AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

IQST

***Sponsored by Corporate Ads, LLC.

iQSTEL logo (PRNewsfoto/iQSTEL)

‍

They just reported $128.8 million in preliminary unaudited revenue for the first half of 2025, with June alone contributing $27.3 million

‍

‍

Hello Everyone,

Our last profile jumped a clean 100% from the open during the session and we have seen some other movers this month. July has been impressive.

We have a few companies that we are going to bring to your attention in the coming days.

This next one is a 2 time mover that is new to the Nasdaq and growing revenues at a substantial rate.

You will remember this one for sure……. the first time we looked at It, we saw an opening on that session of 8.92. Then the next session it hit 14.70 on record interest. It was a huge 65% winner for us.  The second time we profiled the company it ran over 10% on strong interest.

If you haven’t researched this one in the past, we are urging you to take a look at it right now here at these levels.

This one has sat in a tight range all of July and it is sitting right now at a place where it definitely has room to run. The ceiling on this company is HIGH with their massive revenues and big relationships already in place.

The growth alone is jaw dropping as the company claims to be on track to 1 Billion in Revenues by 2027. It just uplisted to the Nasdaq back in May.The CEO says the company came to the Nasdaq with 20,000 shareholders.

The float has to be tiny. The company just completed a 1 for 80 reverse a few months back.

IQST is a multinational technology company offering cutting-edge solutions in Fintech, Blockchain, Artificial Intelligence (AI), and Cybersecurity. Telecom, High-Tech Telecom Services (eSIM, roaming, cloud), with over 600 global business relationships.They deliver high-value, high-margin services to its extensive global customer base.r

In 2024, IQSTEL reported $283 million in revenue, yet their market cap remained at only about 10% of that figure. They also achieved 96% year-over-year revenue growth but valuation has not kept pace with performance, leaving plenty of room for growth for IQST.

• Robust Telecom Operations – iQSTEL provides international wholesale voice and SMS transport for more than 35 leading telecom operators—including Verizon, Vodafone, and China Mobile— and hundreds of Tier 2 carriers via interconnects with over 600 carriers across 20+ countries. In the past year, voice traffic volume increased 24% and SMS traffic rose 23%, underscoring growing demand and customer satisfaction.

• Relationship-Driven Industry, Relationship-Driven Company – Success in international telecom hinges on experience, trust, and network reach. iQSTEL’s core competitive edge lies in management’s extensive global relationships. CEO Leandro Iglesias and his executive team bring decades of deep industry expertise, which they’ve used to convert personal contacts into longstanding commercial relationships and favorable interconnection agreements.

• Asset-Light Model = High Returns – Rather than investing in capital-intensive infrastructure, iQSTEL leases capacity in an oversupplied global telecom market. This asset-light approach significantly enhances return on investment and operational flexibility, enabling the company to scale rapidly and pivot as market opportunities arise.

• Disciplined, Strategic M&A Platform – iQSTEL has completed nine acquisitions since going public in 2018. These deals have been carefully sourced through existing industry relationships—every acquired CEO was personally known to Mr. Iglesias. Post-acquisition, these founders remain in place under earn- out agreements, preserving operational continuity and customer relationships. The company’s strategy of acquiring an initial 51% stake enables efficient capital allocation while maintaining majority control.

• Accelerating Revenue, Near-Term Profitability – Revenue grew 96% last year to $283 million, and we estimate that it is on the cusp of generating positive EBITDA. Management guides to a $400 million annualized revenue run rate by year-end, including a recent acquisition expected to contribute approximately $85 million in additional annual revenue. The longer-term goal is $1 billion in revenue, positioning iQSTEL alongside peer leaders such as IDT (NYSE-IDT) and Cogent (NASDAQ-CCOI).

• Attractive Valuation with Significant Upside – Telecom comparables trade at an average EV/EBITDA multiple of 9.2x 2026E, with iQSTEL’s closest comps (IDT and Cogent) trading at a 15% premium.

iQSTEL is a Miami-based telecom services company providing international services under a unique asset-light model. The business was founded by the former head of CANTV’s international business in 2008 as Etelix and then merged with a public shell company to go public in 2018. Since then, the company has completed nine acquisitions, with revenue growing rapidly, and more growth is expected. This year, it is consolidating acquisitions, moving both voice and SMS traffic to its operating subsidiaries with the lowest cost routing via international agreements. It is also working with its vendor to consolidate its operations onto a single platform.

The company has four key competitive advantages:

• Exceptional Industry Relationships – CEO Leandro Iglesias brings 27 years of telecom experience, including leadership at CANTV—formerly Venezuela’s top-tier national carrier and once partly owned by Verizon and Telefónica. His personal network spans the globe and includes current executives at many of the world’s largest carriers.

• Strategic Customer Acquisition – Management has leveraged its relationships to secure over 35 major international telecom customers and hundreds of tier 2 customers. These are high-volume, recurring relationships that drive consistent growth and reduce churn risk.

• Buyer Advantage in Oversupplied Market – Management also utilizes the same connections to secure the lowest-cost routing and termination agreements with global telecom carriers. Telecom is an opaque industry, and personal connections are important in negotiating favorable terms. The company benefits because the telecom industry has overbuilt, deploying too many network assets, so negotiations favor buyers like iQSTEL.

• Proven Acquisition Strategy – Every acquisition the company has completed has been of a company founded and run by an entrepreneur that Mr. Iglesias has known personally for many years. His modus operandi is to acquire an initial 51% stake, keep management on board, and give them earn-outs for continuing to perform after the acquisition.

iQSTEL is the Combination of Nine Acquisitions

Acquisitions are a key to the company’s growth strategy. To date, it has completed nine acquisitions to get the company to its present state of five operating voice telecom subsidiaries, two operating SMS subsidiaries, two fintech subsidiaries, and one metaverse joint venture.

Consideration paid for the eleven acquisitions has totaled $17.57 million, including the reverse merger of the CEO’s original business into a shell company. By comparison, the company has a roughly $30 million market cap, only owns 51% stakes in six business units and a 75% stake in one, with 100% stakes in only the original Etelix and QGlobal SMS acquired in 2020. To bring its stake up to 100% in each of its business units would require an estimated $11.3 million at the original purchase prices; however, much of this is expected to be paid in shares.

The founders have been known professionally to the CEO for several years and are willing to stay on and run the business with earnouts for performance. Keeping the founders in place is important because they have personal relationships with the customers.

Since Inception, iQSTEL Has Completed Nine Acquisitions

‍

MAIN CUSTOMERS

‍

IQST – IQSTEL Issues Recap Shareholder Letter Highlighting $2 Debt Reduction Per Share, $400 Million Run Rate in Q3 (Ahead of Schedule), and Analyst Coverage Targeting $18-$22 Price Range

Published

Jul 21, 2025 8:30am EDT

Company Recaps Milestones After Two Months on NASDAQ: Accelerated Growth, Strengthened Balance Sheet, Launch of High-Margin Tech Products, and Strategic Acquisition of Globetopper

NEW YORK, July 21, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST) has released a shareholder letter reflecting on its strategic and financial achievements during its first two months trading on the NASDAQ. The letter outlines the company’s accelerating growth trajectory, successful execution of its high-margin technology strategy, strengthened capital structure, and enhanced institutional visibility.

logo

‍

In this letter, IQSTEL’s CEO shares key business highlights, including surpassing a $400 million revenue run rate earlier than projected, the launch of AI-powered platforms like IQ2Call.ai, and the addition of $60–70 million in revenue through the Globetopper acquisition. The company also emphasizes its $2-per-share debt reduction, improving shareholder value and positioning IQSTEL to achieve its long-term $1 billion revenue goal by 2027.

Dear Shareholders,

As we mark our second month trading on the NASDAQ, I want to take this opportunity to reflect on the tremendous progress we’ve made and share with you why we believe the road ahead for IQSTEL is not just promising — it’s transformative. The Board of Directors and officers of the company are both excited and honored to have hit these major milestones. We remain fully committed to creating long-term shareholder value and driving the continued growth of the company.

A Strong Start to 2025 – Accelerating Toward a New Era

We’ve reported $128.8 million in preliminary unaudited revenue for the first half of 2025, with June alone contributing $27.3 million — a clear sign that our commercial momentum is not just holding strong, but accelerating.

Starting July 1st, we began consolidating revenues from our newly acquired subsidiary, Globetopper, which is expected to add an additional $5 to $6 million per month. With this acceleration, we now expect to surpass a $400 million revenue run rate during Q3, several months ahead of our original year-end target.

But we’re not just growing our top line — we’re strengthening our bottom line. Our strategy is focused on building a scalable, high-margin business model, and our recent launches of IQ2Call.ai and the upcoming AI-powered cybersecurity services through Cycurion are driving exactly that. These tech offerings are not only innovative — they are designed to increase both Net Income and Adjusted EBITDA, paving the way for sustainable, profitable growth.

To learn more about our revenue growth and projected run rate, click here.

Globetopper Acquisition – Strengthening Our Fintech Business

On July 1st, we completed the acquisition of Globetopper, a move that adds $60–70 million in annual revenue with positive EBITDA. This acquisition also plays a key role in relaunching our fintech division.

We are actively working on a plan to grow Globetopper’s revenue to $100 million annually, with at least $1 million in EBITDA, further reinforcing our leadership in global telecom and fintech services. We are planning to reach a 400M run rate in Q3, with a revenue mix of 80% telecom and 20% fintech.

To learn more about the Acquisition of GlobeTopper, click here.

Independent Analyst Coverage – Market Recognition Growing

We are proud to be the subject of a new independent analyst report by Hills Research, which initiated coverage on IQSTEL with a price target range of $18 to $22 per share.

This endorsement came after extensive due diligence, including in-person meetings at our Florida office and deep analysis of our technology platform. This report reflects growing institutional awareness and validation of our strategy and value proposition.

To access the Hills Research Report, click here.

High-Margin Tech Products – The Future Is Now

In July, we launched IQ2Call.ai, our AI-powered call center platform featuring real-time voice AI, multilingual support, and adaptive scalability with zero wait times. IQ2Call targets the $750 billion global call center industry, delivering unmatched performance and compliance.

This is a transformative milestone in our vertical integration strategy. In both Spain and the U.S., IQ2Call is already being deployed, and we’re currently closing deals that will accelerate adoption further.

To learn more information about our new product IQ2Call, click here.

Additionally, through our partnership with Cycurion, we’re also preparing to enter the cybersecurity sector, delivering new era of AI-driven cybersecurity services tailored for the telecom industry. Thanks to our deep, long-standing relationships with hundreds of global telecom operators, we will be able to cross-sell these offerings and maximize return per customer.

To learn more information about our partnership with Cycurion, click here.

Strengthening Our Balance Sheet – A Healthier, Leaner IQSTEL

We recently reduced our debt by $6.9 million, converting part into common shares and the remainder into preferred equity — all of which is already reflected in our capital structure.

This means we’ve effectively eliminated around $2 of debt per share, creating significant shareholder value. These actions also reflect investor confidence in our long-term vision to become a $1 billion revenue company by 2027.

To learn more about our debt reduction, click here

Investor Access and Institutional Outreach

In early July, we released a comprehensive investor presentation outlining our strategy, business model, financials, and future vision. We are starting actively presenting to institutional investors and family offices, encouraging them to acquire and hold IQST shares directly on the open market — with no dilution involved.

To access to our Investors Deck, click here

Looking Ahead – Halfway to a Billion

From just $13 million in 2018 to nearly $300 million in 2024, our story has been one of strategic growth and bold execution.

Now, with a healthy balance sheet, a scalable telecom and fintech platform, and a pipeline of high-tech, high-margin products, we are well on our way to:

  • Achieving our $340 million 2025 revenue forecast
  • Exceeding a $400 million run rate in Q3
  • Ultimately reaching $1 billion in annual revenue by
  • Driving sustained growth in Net Income and Adjusted EBITDA

And this is just the beginning.

With your continued trust and support, IQSTEL is writing the next chapter in technology-driven telecom innovation — and you’re part of it.

Sincerely,

Leandro Jose IglesiasPresident & CEOIQSTEL Inc. (Nasdaq: IQST)

IQST – IQSTEL Strengthens Equity Position with $6.9 Million Debt Cut — Almost $2 Per Share

Published

Jul 9, 2025 8:30am EDT

NEW YORK, July 9, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST), a leading global telecommunications and technology company, is pleased to announce a significant reduction of $6.9 million in debt from its balance sheet, marking a strategic milestone in the company’s ongoing financial strengthening and long-term growth plan.

This debt reduction will have a direct and positive impact on the company’s net stockholders’ equity, which stood at $11.34 million as of Q1 2025. The reduction was achieved through a combination of debt conversions into common shares and Series D Preferred Shares. The conversion into Series D Preferred Shares reflects investor confidence in IQSTEL’s strategic plan to reach $1 billion in annual revenue by 2027.

In addition to improving the company’s capital structure, this transaction provides $0.92 million in interest savings, directly enhancing IQSTEL’s cash flow and operational flexibility.

“Our company is $6.9 million stronger than it was last week — that’s a significant step,” said Leandro Iglesias, CEO of IQSTEL. “We are fully committed to reaching our $1 billion revenue target by 2027, and actions like this reinforce our foundation and demonstrate our determination to build long-term shareholder value. A simple and clear way to see the impact of this move is that we’ve reduced our debt by approximately $2 per share. That’s a direct and tangible creation of value for our shareholders.”

At the same time, IQSTEL is actively working on improving its adjusted EBITDA while reinforcing its balance sheet — a dual approach that the company believes is the most effective path to maximize shareholder value.

This strategic move comes in conjunction with the fully executed acquisition of Globetopper, and the release of a favorable independent analyst report by Litchfield Hills Research, available here: https://hillsresearch.com/wp-content/uploads/2025/07/LHR-IQST-intitiation-report.pdf.

The execution date of the debt reduction was July 3, 2025, and the financial impact will be reflected in the company’s Q3 2025 Form 10-Q filing. Further details have been disclosed in the company’s corresponding Form 8-K filed with the SEC.

With these developments, IQSTEL begins the second half of 2025 on a remarkable path — stronger, leaner, and more prepared than ever to deliver on its ambitious vision.

NEWS


IQST – IQSTEL Issues Recap Shareholder Letter Highlighting $2 Debt Reduction Per Share, $400 Million Run Rate in Q3 (Ahead of Schedule), and Analyst Coverage Targeting $18-$22 Price Range

3 days ago

IQST – IQSTEL Reports $128.8 Million in Preliminary Revenue for First Half of 2025

Jul 17, 2025

IQST – IQSTEL Expands Tech Portfolio with Launch of IQ2Call, Delivering Vertical AI-Telecom Integration to Target the $750B Global Market

Jul 15, 2025

IQST – IQSTEL Strengthens Equity Position with $6.9 Million Debt Cut — Almost $2 Per Share

Jul 9, 2025

IQST – IQSTEL Confirms Closing of GlobeTopper Acquisition, Forecasting $34M Revenue and Positive EBITDA for H2 2025

Jul 1, 2025

IQST – IQSTEL Reports $101.5 Million in Preliminary Net Revenue for Jan-May 2025, On Track to Meet $340 Million Annual Forecast

Jun 24, 2025

IQSTEL and Cycurion (CYCU) Unveil Plans for AI-Powered Next-Generation Cybersecurity Platform, Targeting the Global Telecom Industry

Jun 18, 2025

IQST – IQSTEL and Cycurion (CYCU) Unveil Plans for AI-Powered Next-Generation Cybersecurity Platform, Targeting the Global Telecom Industry

Jun 18, 2025

IQST – IQSTEL (NASDAQ: IQST) Issues June Update: $77.8M Preliminary Revenue, GlobeTopper Acquisition, NASDAQ Momentum, and a Clear Path to $1B

Jun 11, 2025

IQST – IQSTEL Reports Preliminary $77.8 Million in Revenue Through April 2025 — Confirms Full-Year Guidance and Fast-Track to $400M Run Rate

Jun 5, 2025

Exclusive Interview with Leandro Iglesias, CEO of IQSTEL, Inc. (Nasdaq: IQST); Acquiring Majority Interest in Fintech Innovator GlobeTopper

Jun 3, 2025

IQST – IQSTEL Sparks Rapid Global Fintech Expansion with GlobeTopper Acquisition — Fast-Tracking $1 Billion Growth Plan

May 29, 2025

IQST – IQSTEL Releases New Investor Deck as Invitation for Long-Term Shareholders to Enter the Open Market

May 22, 2025

IQSTEL (NASDAQ: IQST) Issues Follow-Up Shareholder Letter Highlighting NASDAQ Benefits, $57.6M Q1 Revenue, and $14.58 Assets Per Share on Path to $1 Billion

May 20, 2025

IQST – IQSTEL Reports $57.6M Q1 Revenue in First NASDAQ Shareholder Letter, Reaffirms Path to $1 Billion by 2027 as Global Tech Evolution Accelerates

May 15, 2025

IQST – IQSTD – IQSTEL to Begin Trading Tomorrow on NASDAQ Capital Market Under Ticker: IQST

May 13, 2025

IQSTD – IQST – IQSTEL Powers Forward: From Global Telecom to High-Tech Innovator with QXTEL Leading New eSIM Rollout

May 13, 2025

Exclusive Interview with Leandro Iglesias, CEO of IQSTEL, Inc. (Symbol: IQSTD) Regarding Global Technology Small Share Structure Positioned to Benefit Shareholder Value via NASDAQ Uplisting and Strong Revenue Growth Aimed at $1 Billion by 2027

May 8, 2025

IQSTEL Announces Strategic Decision to Uplist to NASDAQ and Executes Reverse Stock Split to Meet Minimum Listing Requirements

May 2, 2025

iQSTEL Announces Reverse Stock Split in Preparation for Uplist to Nasdaq

May 1, 2025

‍

MANAGEMENT

‍

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FOUR THOUSAND ONE HUNDRED FIFTY USD BY CORPORATE ADS LLC FOR A ONE DAY IQST AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

DEVS

***Sponsored by LFG Equities Corp and Disseminated on behalf of DevvStream Corp

DevvStream Adds Two Indonesian Waste-to-Energy Agreements, Strengthening Asia Environmental Asset Program and Diversifying Portfolio

READ THE INVESTOR PRESENTATION HERE

_________________________

Hello Everyone,

The last time we brought you this one just weeks back It saw an average trade of .39 sense on the day. The very next session it hit 1.35 for a 250% move overnight. It was impressive.

We want you to research this one again while it is sitting here around just .40.

In the last 4 sessions it has had 2 double digit swings to the upside.

Pull up DEVS right away.

‍You want to make sure you research this one thoroughly and read everything we have to say before you start your own due diligence. .

DevvStream just signed a potentially game-changing Memorandum of Understanding with Fayafi Investment Holding — one of the UAE’s most forward-thinking investment platforms, to launch a global joint venture called Fayafi x DevvStream Green Ventures.

This joint venture would be backed by an initial funding commitment of $100 million and is built to deploy capital into climate infrastructure projects around the world, especially in fast-growing, underserved regions.

DevvStream will own 20% of the venture and serve as the operational and technical lead, unlocking revenue from environmental asset generation and from the returns on these investments. DEVS will be able to make money from both the environmental assets they generate and the returns from the investments through their percentage ownership of the JV.

With this structure, DevvStream gains direct access to the Middle East, a region with a massive need for carbon credits, thanks to the carbon-intensive nature of the oil and gas industry.

The combination of Fayafi’s institutional network and capital with DevvStream’s execution engine could prove incredibly powerful, creating a scalable platform for environmental impact and value creation.

If you really want to understand DEVS you need to understand what carbon credits are. They are a financial tool designed to help organizations advance decarbonization efforts by funding environmentally conscious projects. The carbon market is already a $1T market according to many reports which also expect it to double over the next 4 years or so.

 Carbon Credit Market Size 2025 to 2034

‍

DEVS is a leading authority in the use of technology in carbon project development.

The company’s mission is to create alignment between sustainability and profitability, helping organizations achieve their climate initiatives while directly improving their financial health.

The company is involved in a number of green initiatives with the ultimate goal of reducing the impact of climate change.

DEVS works with governments and corporations worldwide to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissioBns, and sequester carbon directly from the air. DEVS also helps these organizations meet their net zero goals by providing them access to high-quality carbon credits.

What they do is  partner with companies that have technologies that are eligible for generating carbon credits, producing the credits on their behalf.  

DevvStream then gets 25% of the credits that are generated for the life of the project. This has the potential to be highly lucrative since the company isn’t investing in the project itself.  

The company has more than 140 of these projects in its pipeline, with more than a dozen signed contracts representing an opportunity to generate 30 million+ credits per year.

Over the past year, the company has announced several signed contracts with EV charging networks to help them generate carbon credits. These include:

  • Texas-based Go-Station
  • New York City-based Green Energy Technology
  • India-based E-Fill Electric
  • Florida-based OK2Charge

Another major development was there of a 50% equity stake in Monroe Sequestration Partners (MSP) and its carbon sequestration operations.

DevvStream Adds Two Indonesian Waste-to-Energy Agreements, Strengthening Asia Environmental Asset Program and Diversifying Portfolio

Published

Jun 9, 2025 11:00am EDT

MoUs with PT Tren Solusi Transformasi Indonesia and PT Kartika Satu Graha Mandiri introduce new I-REC and carbon-credit revenue streams alongside DevvStream’s previously announced Indonesian hydro asset

Calgary, Alberta–(Newsfile Corp. – June 9, 2025) – DevvStream Corp. (NASDAQ: DEVS) (“DevvStream” or the “Company“), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced two new memoranda of understanding (“MoUs“) in Indonesia:

  • PT Tren Solusi Transformasi Indonesia — municipal waste-to-energy (“WtE“) facility in West Java.
  • PT Kartika Satu Graha Mandiri — WtE project converting landfill waste in Depok City into grid-connected renewable power.

Pursuant to each MoU, DevvStream expects to structure, certify, and market International Renewable Energy Certificates (“I-RECs“) and verified carbon credits, which has the potential to generate recurring revenue once environmental assets are issued. The MoUs are non-binding and subject to the successful execution of definitive agreements.

Strengthening a Diversified Southeast-Asia Pipeline and Overall Portfolio

  • Expanding ASEAN footprint. These anticipated WtE projects follow DevvStream’s previously announced hydroelectric agreement in South Sulawesi, Indonesia, as well as the Company’s solar energy collaboration in Medellin, Philippines, underscoring diverse potential growth across the region.
  • Large addressable WtE market. According to Mordor Intelligence, the Southeast Asia WtE sector is projected to grow from (US)$4.22 billion in 2025 to (US)$7.70 billion by 2030, a 12.8% CAGR.
  • Diversified revenue sources. WtE now joins hydro, solar, carbon sequestration, biogas and other asset classes in DevvStream’s revenue mix.

“By entering into MoUs for two Indonesian waste-to-energy projects, we aim to deepen our ASEAN footprint alongside the hydro asset announced in South Sulawesi and our solar collaboration in Medellin, Philippines,” said Sunny Trinh, CEO, DevvStream. “Waste-to-energy is among the region’s fastest-growing segments, projected to expand from roughly US $4 billion today to about US $7.7 billion by 2030. Adding this vertical—alongside hydro, solar, biogas, and carbon sequestration—further diversifies our prospective revenue base and potentially positions DevvStream to deliver high-integrity assets while addressing Southeast Asia’s dual challenges of waste and power.”

About DevvStream

DevvStream Signs Carbon Management Agreement with Energy Efficient Technologies

Published

Jun 23, 2025 8:14am EDT

Partnership expands DevvStream’s pipeline with efficiency-based environmental assets and shared energy-savings revenue

Calgary, Alberta–(Newsfile Corp. – June 23, 2025) – DevvStream Corp. (NASDAQ: DEVS), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced a carbon-management agreement with Energy Efficient Technologies (“EET“). EET is an engineering firm that reduces electricity use in commercial buildings by an average 8%-35% and has validated savings for numerous large-scale clients, including a global hospitality group operating more than 8,000 hotels across more than 130 countries, the world’s largest quick-service restaurant network, and one of the world’s largest brewing companies, with flagship beer brands sold in over 100 markets.

Deal highlights

  • Two revenue streams. Pursuant to the agreement, DevvStream will receive revenue from EET’s carbon credits and international renewable energy certificates (“I-RECs“) and share in verified utility-bill savings.
  • New vertical. Adds building-efficiency assets to DevvStream’s hydro, solar, waste-to-energy, carbon-capture, and biogas portfolio of projects and partners.
  • Large addressable market. EET estimates that deploying its CryoGenX4™ across 8,000 data centers could save (US) $20 billion in power costs, cut 166 billion kWh, and avoid 117 million tonnes of CO₂ per year—showing the scale DevvStream can help monetize.
  • Growing demand. Companies seeking scope-2 reductions increasingly view energy-efficiency credits as a cost-effective decarbonization path.

“We believe EET’s proven record of double-digit energy savings positions us to unlock a high-value stream of efficiency-based credits and cost-sharing revenue,” said Sunny Trinh, CEO of DevvStream. “By layering shared savings on top of carbon- and I-REC monetization, we anticipate further diversifying DevvStream’s income while helping businesses cut costs and emissions.”

“Energy Efficient Technologies has delivered—and independently verified—double-digit energy-use reductions for clients such as Marriott, McDonald’s cold-chain distribution network, Anheuser-Busch, and Cogent Communications data centers,” said Joe Mearman, CEO of EET. “DevvStream’s transparent credit-certification process and global buyer reach provide a trusted pathway to convert those proven savings into high-integrity carbon credits and I-RECs, allowing our customers to capture additional environmental and financial value while we remain focused on engineering efficiency at scale.”

About DevvStream

Founded in 2021, DevvStream is a leading carbon management firm specializing in the development, investment, and sale of environmental assets, energy transition, and innovative carbon management solutions. The Company’s mission is to create alignment between sustainability and profitability, helping organizations achieve their climate initiatives while directly improving their financial health.

With a diverse approach to energy transition and carbon markets, DevvStream operates across three strategic domains: (1) an offset portfolio consisting of nature-based, tech-based, and carbon sequestration credits for immediate sale to corporations and governments seeking to offset their most difficult-to-reduce emissions; (2) project investment, acquisitions, and industry consolidation to extend the company’s reach, allowing it to become a full end-to-end solutions provider; and (3) project development, where the company serves as project manager for eligible activities such as EV charging or renewable energy generation in exchange for a percentage of generated credits or I-RECs.

For more information, please visit www.devvstream.com.

About Energy Efficient Technologies

Since 1988, the Energy Efficient Technologies team has been passionate about helping the environment.

The company’s employees began as contractors working with the United States Navy, helping to automate the energy and control systems of nuclear submarines, warships, and aircraft carriers. Their work allowed personnel to focus on their primary tasks, while reducing energy, fuel usage, operation and maintenance costs and improving reliability and survivability. Today, Energy Efficient Technologies has become an industry leader through its continued research and applications. The company’s goal is to help every client reduce their carbon footprint while becoming more energy efficient and profitable.

DevvStream Corp and Fayafi Investment Holding Sign MoU to Explore Creation of “Fayafi x DevvStream Green Ventures” to Accelerate Global Sustainability Investments

MAY 7, 2025 11:30AM EDT

Proposed capital-light joint venture aims to unlock high-impact decarbonization and energy transition opportunities

Calgary, Alberta–(Newsfile Corp. – May 7, 2025) – DevvStream Corp. (NASDAQ: DEVS) (“DevvStream” or the “Company“), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced that it has signed a Memorandum of Understanding (“MoU“) with Fayafi Investment Holding (“Fayafi“), one of the UAE’s most forward-thinking and diversified investment platforms. The agreement outlines the intent to launch Fayafi x DevvStream Green Ventures, a global joint venture designed to accelerate investment in decarbonization and climate infrastructure projects worldwide.

Fayafi x DevvStream Green Ventures is expected to combine DevvStream’s operational and technical expertise with Fayafi’s capital resources, institutional network, and ESG-focused investment strategy. The platform would focus on identifying, funding, and scaling a pipeline of environmental projects across high-growth regions. Firm agreements are expected in Q2 2025, with initial project deployments targeted for Q3/Q4 2025. The initial funding commitment is expected to be $100 million, with the potential to scale significantly based on project performance and capital deployment efficiency.

“Fayafi x DevvStream Green Ventures is envisioned as a purpose-built platform to meet the needs of climate and energy transition investment in a changing world,” said Carl Stanton, Chairman of DevvStream. “Fayafi, as a strategic and financial partner, represents an ideal counterpart to help us scale quickly and responsibly, providing significant upside to DevvStream investors.”

Bobby Campbell, the Chief ESG Investment Officer for Fayafi Investment Holding added, “This MoU marks an important step toward the future of climate finance. We believe in the potential of this partnership and are committed to continuing the dialogue with DevvStream.”

The joint venture will be structured as an independent entity, with ownership expected to be allocated 80% to Fayafi and 20% to DevvStream, and economics shared on a pro-rata basis. This capital-light model enables DevvStream to expand its global presence in energy transition and environmental assets while unlocking recurring revenue streams from project management, consulting, and carbon monetization—with minimal upfront investment.

Fayafi will serve as the financial and strategic engine of the venture, leveraging its institutional relationships and global network to drive market access, regulatory approvals, and execution at scale. The MoU also grants DevvStream exclusivity during the feasibility phase and a first right of refusal on carbon-related opportunities, underscoring a shared commitment to long-term alignment and disciplined project selection.

As operational and technical lead, DevvStream would be responsible for identifying and evaluating high-impact sustainability projects, structuring and registering environmental assets under global standards, managing implementation, and overseeing the full lifecycle of carbon credit generation and monetization. Fayafi’s role as financial sponsor and market enabler would complement DevvStream’s execution, supporting efficient scaling into undercapitalized markets.

This proposed joint venture marks a pivotal step in DevvStream’s strategic evolution, allowing the Company to expand its footprint, enhance monetization pathways, and deliver scalable climate impact through a collaborative global platform.

About Fayafi Investment Holding

Fayafi Investment Holding Limited is a global investment platform headquartered in Dubai, UAE, with a diversified portfolio across sustainability, AI, defense, biotech, and real estate. As the first UAE-based company listed on the Vienna Stock Exchange and the issuer of a bankable certificate under the SIX Swiss Exchange, Fayafi is widely recognized for its innovative, long-term investment philosophy and commitment to ESG leadership.

______________

‍

MONROE PROJECT

Project Revenues are expected to be generated from:

•⁠  ⁠Storage fees from accepted CO2 to be sequestered

•⁠  ⁠Up to 260M 45Q Tax Credits

•⁠  ⁠Sale of up to 260M carbon credits

45Q tax credits are generated via a US tax credit program that incentivizes carbon capture, utilization, and storage (CCUS) projects
•⁠  ⁠45Q tax credits are transferable and are valued at up to $85 per ton of CO2 stored.

‍

I-REC

Late last year, DEVS announced that it will be diversifying its revenue streams to include renewable energy certificates (I-RECs).

An I-REC is generated when a power plant generates 1MWh of renewable energy. It can then be sold to companies that need them to maintain their commitments to renewable energy.

These days, some of the largest companies in the world — heavyweights such as  Apple, Google, Microsoft, and Samsung — have commitments to use 100% renewable energy, which often requires buying I-RECs.
DevvStream has secured exclusive agreements in Asia’s renewable energy market:
Medellin Solar Power Facility (Philippines): A 730 MWp project capable of generating over 1.2 million I-RECs per year.
PT.Siteba Hydroelectric Facility (Indonesia): An already operational hydro facility expected to generate I-RECs in 2025

Polar Asset Management Partners Inc. Acquires Significant Stake in DevvStream Corp

Transaction Overview

Polar Asset Management Partners Inc. recently executed a notable transaction by acquiring 558,415 shares of DevvStream Corp on December 31, 2024. The shares were purchased at a price of $0.752 each, marking a strategic move by the firm. This acquisition represents a new holding in Polar Asset Management’s portfolio, with DevvStream Corp now accounting for 0.01% of the firm’s total investments. The transaction reflects Polar Asset Management’s interest in expanding its portfolio within the technology and environmental sectors.

Polar Asset Management Partners Inc is a well-regarded firm known for its expertise in value investing. The firm manages an equity portfolio valued at $3.44 billion, with significant investments in the Financial Services and Technology sectors. Some of its key holdings include Sprott Physical Gold Trust, Sprott Physical Silver Trust  and Insulet Corp. The firm’s strategic investment decisions are guided by a focus on long-term value creation and market opportunities.

NEWS


RETRANSMISSION: DevvStream Signs Carbon Management Agreement with Energy Efficient Technologies

Jun 23, 2025

DevvStream Signs Carbon Management Agreement with Energy Efficient Technologies

Jun 20, 2025

DevvStream Adds Two Indonesian Waste-to-Energy Agreements, Strengthening Asia Environmental Asset Program and Diversifying Portfolio

Jun 9, 2025

DevvStream Corp and Fayafi Investment Holding Sign MoU to Explore Creation of “Fayafi x DevvStream Green Ventures” to Accelerate Global Sustainability Investments

May 13, 2025

DevvStream Affiliate Monroe Sequestration Partners Signs Agreement with Southern Energy to Anchor Major Carbon Capture Project in Louisiana

May 8, 2025

DevvStream Corp and Fayafi Investment Holding Sign MoU to Explore Creation of “Fayafi x DevvStream Green Ventures” to Accelerate Global Sustainability Investments

May 7, 2025

DevvStream Announces Additional Investment

Mar 19, 2025

DevvStream Boosts Carbon Offset Initiative Through E-Commerce Partnerships

Mar 18, 2025

DevvStream Accepted into Singapore Carbon Market Alliance (SCMA), Focused on Carbon Credits Aligned with Article 6

Feb 3, 2025

DevvStream Discloses Nasdaq Notice and Provides Update

Jan 28, 2025

DevvStream Accepted into Singapore Carbon Market Alliance (SCMA), Focused on Carbon Credits Aligned with Article 6

Feb 3, 2025

DevvStream Discloses Nasdaq Notice and Provides Update

Jan 28, 2025

DevvStream Launches Carbon Offset Sales Initiative Targeting Corporations and Consumers

Dec 19, 2024

DevvStream Adds Hydroelectric Power Facility to its Asia I-REC Program

Dec 18, 2024

DevvStream Enters Biogas Market via Partnership with Methane Renewable Energy Leader

Dec 12, 2024

DevvStream Enters REC Market in Asia with Medellin Solar Power Facility Partnership

Nov 29, 2024

DevvStream Provides Bi-Weekly Status Update

Nov 20, 2024

DevvStream Provides Update on Carbon Sequestration Facility Development

Nov 19, 2024

‍

MANAGEMENT

Sunny Trinh

CHIEF EXECUTIVE OFFICER

As co-founder and CEO, Sunny is responsible for building and executing DevvStream’s project pipeline through his vast network of sustainable technology and corporate relationships. He has spent over 25 years in the technology sector and directly in developing new verticals in ESG and carbon markets.

He also serves as the Chief Digital Alchemist for Devvio Inc., where he develops new business models in the ESG and carbon markets.  Prior to DevvStream, Sunny led innovation as VP of Ecosystem at Avnet Inc. (AVT: NASDAQ). He was also the COO for Jooster and VP of Sales for Arrow Electronics (ARW: NYSE) where he led the design team for a Corvette driven by a quadriplegic.

Sunny served as CEO for 9:Fish Surfboards and was an adjunct professor for Cal Lutheran University’s MBA program where he started the school’s technology tract. Sunny holds a B.S. and M.E in Engineering, an M.B.A. degree, and holds several patents on electronic accessories for cell phones.

David Goertz

CHIEF FINANCIAL OFFICER

David provides accounting, assurance, taxation and business advisory services to private and public companies, not-for-profit organizations and incorporated professionals. David has specialized knowledge of the manufacturing, mining, real estate, and technology industries. He also has a keen understanding of public company operations, restructurings, acquisitions and IPOs.

Chris Merkel

CHIEF OPERATING OFFICER

Chris is the VP and Chief Operating Officer of DevvStream. Prior to joining the team, Chris spent 24 years managing strategic customers, growing technical services verticals and held sales leadership roles at Avnet (AVT: NASDAQ) and Arrow Electronics (ARW: NYSE). He has engaged with companies at every stage, from pre-funded startups to global enterprises in markets such as IIoT, consumer, industrial and medical. Additionally, Chris spent 5 years with Sierra Pacific Industries in a general sales and operations management role. He has over 30 years of sales, operations and general management experience successfully managing diverse teams and projects.

Jonathan Miller

CHIEF COMMUNICATIONS OFFICER

An accomplished communications professional with over 20 years of experience developing integrated marcom programs, Jonathan specializes in the automotive, robotics, consumer electronics, sustainability/ESG, and semiconductor domains.

With expertise in brand identity, web design, video development, copywriting, print/layout, public relations, and event management, Jonathan has held several senior positions in the Silicon Valley area, most recently with Ambarella (Nasdaq: AMBA), a leading provider of AI vision processors for edge applications. Prior to that, Jonathan was VP of Advanced Products for a consumer electronics startup whose technology patents were ultimately purchased by Facebook. He was an eighth-grade English teacher for seven years in the Oakland Unified School District and received his bachelor’s degree from Stanford University.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND ONE HUNDRED FIFTY USD BY LFG EQUITIES CORP FOR A ONE DAY DEVS AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

NEXM

***Sponsored by LFG Equities Corp & Disseminated on behalf of Nexmetals Mining Corp

NexMetals Mining Corp.

NexMetals Begins Trading on the Nasdaq Under the Symbol NEXM and continues on the TSXV 

‍Donald Trump announced a 50% tariff on copper imports, stunning the market and sending prices surging past $5.60 per pound

‍

________________________

‍Hello Everyone,

Today’s profile exploded past 8 bucks and still looks strong after it just made a massive move. 

An urgent situation just came across my desk hours ago. This is another company that just uplisted and has actually been moving north. Sometimes when we see companies like this move up, they lose a significant portion of their value immediately. This one has bucked the trend, making it a great time to research it.

Why this one? There are several reasons but let’s dive in:

On July 8th, Donald Trump announced a 50% tariff on copper imports,¹stunning the market and sending prices surging past $5.60 per pound. 

image1 4 Trump Just Lit the Fuse on a Copper Crisis and This Junior Developer Could Be One of the Biggest Beneficiaries

It’s one of the boldest trade moves of his presidency and a game-changer for the global copper supply chain.

The message is clear: the US wants to reduce reliance on foreign copper.

It’s not just a commodity anymore. It’s a strategic asset.

And that means one thing…

The market is shifting toward copper developers tied to domestic and allied supply chains.

Global demand for copper is exploding, driven by EVs, AI infrastructure, defense, and energy transition megaprojects.²

But supply is bottlenecked. Major discoveries have collapsed by over 80% since 2010.³

40% of current output comes from politically unstable jurisdictions.⁴ And it takes over 15 years, on average, to build a new mine from scratch.⁵

Source: bhp.com⁶

Now layer in tariffs and suddenly, companies with clean corporate structures, strong copper assets, and projects in stable, mining-friendly regions look like some of the most strategic opportunities in the sector.

That’s where NEXM comes in.

This newly restructured copper-nickel explorer holds two past-producing mines in Botswana—one of the most politically stable jurisdictions on the planet, often called “the Switzerland of Africa.”⁷

In June 2025, the company completed a 20-for-1 share consolidation, bringing its total share count to just ~21.45 million — a critical move to support an the recent Nasdaq uplisting, which could provide the company exposure to significantly larger pools of US capital.

NexMetals isn’t just sitting on potential, they already control a newly confirmed 24.7 Mt (Inferred) and 3 Mt (Indicated)⁸ averaging 2.92-3.40% copper equivalent of defined high-grade copper-nickel-cobalt sulphide resources at Selebi⁹ — with high-grade zones identified and aggressive expansion drilling now underway.

NexMetals Mining Corp. NEXM also holds the past-producing Selkirk Mine, where a newly published NI 43-101 resource outlines an additional 44.2 Mt (Inferred) of copper-nickel-palladium-platinum sulphide mineralization averaging 0.81% copper equivalent  — providing a second major growth platform and even more exposure to critical metals.

Even better, they’ve secured a CA$67 million recapitalization¹⁰ — led by Frank Giustra’s Fiore Group, a group with deep mining sector success and EdgePoint Investment Group, one of Canada’s top institutional investors.

And with critical minerals now designated a national security priority by the US, Europe, and Canada, companies like NexMetals— potentially offering new, scalable copper-nickel supply in a stable jurisdiction — are moving to the front of the line.

The project already benefits from infrastructure, permitting, and potential expansion  catalysts.

‍Reviving Two Past-Producing Mines At The Center Of The Critical Minerals Boom

NEXM is a revitalized copper-nickel explorer that’s about to put Botswana’s Selebi and Selkirk mines back on the global map.

Rooted in a Tier One mining jurisdiction, NexMetals controls two past-producing, permitted mines — the Selebi Complex and the Selkirk Mine — once owned and operated by BCL Limited.

Their current resource?

Over 24.7 Mt (Inferred) and 3 Mt (Indicated) of defined high-grade copper-nickel-cobalt sulphide resources — averaging 2.92-3.40% copper equivalent at Selebi¹²— and a further 44.2 million tonnes (Inferred) of copper-nickel-palladium-platinum mineralization averaging 0.81% copper equivalent  at Selkirk.

But here’s what makes NEXM different…

The Selebi North underground is already re-opened, the exploration drifts are advancing, an aggressive drill program is underway and fully funded by a CA$67 million recapitalization backed by Frank Giustra’s Fiore Group and EdgePoint Investment Group.

Frank Giustra Trump Just Lit the Fuse on a Copper Crisis and This Junior Developer Could Be One of the Biggest Beneficiaries

Frank Giustra is not just a financier; he’s a serial mining entrepreneur with a track record that speaks for itself. 

He is notable for helping build Goldcorp,¹³ one of Canada’s most iconic gold producers, and Wheaton Precious Metals,¹⁴ a trailblazer in the streaming model that revolutionized mining finance and has structured and financed multiple world-class mining ventures, resulting in billions in market cap growth. 

He also founded Lionsgate Entertainment, a global film powerhouse — underscoring his rare ability to build billion-dollar companies across sectors.

Giustra’s network — including connections with global financiers, institutional investors, and industry insiders — opens doors to new funding, strategic partnerships, and long-term growth.

Having Giustra as a strategic advisor is a signal to the market: NEXM is on the radar of top-tier institutional investors, and this project is built to scale. 

He’s not just investing in NexMetals; he’s providing the strategic guidance needed to unlock the full potential of Selebi and Selkirk, with the intention of turning both into world-class assets in one of the most stable mining jurisdictions in Africa.

And to support that vision, NexMetals has expanded its leadership bench with two key appointments.

In June 2025, NexMetals welcomed former Lundin Mining finance leader Brett MacKay as CFO to support the company’s capital strategy and markets, while Lindsey Le Ho was appointed Corporate Secretary to bolster governance as the company transitions to a more globally visible platform.

These additions reflect NexMetals’ evolution from a recapitalized junior into a fully integrated, growth-stage company — one equipped not just with projects and capital, but with the team to execute at scale.

Meanwhile, at Selkirk, surface drilling and metallurgical optimization studies are setting the stage for another leg of growth — giving NexMetals not just one, but two catalysts for value creation.

And they’re moving fast.

NexMetals is targeting near-term resource expansions, future production, and strategic optionality in a supply-constrained market desperate for new copper-nickel supply.

NEXM controls two permitted past-producing copper-nickel sulphide mines — Selebi and Selkirk — right in the heart of Botswana’s critical minerals corridor.

Screen Shot 2025 07 04 at 1.13.10 PM Trump Just Lit the Fuse on a Copper Crisis and This Junior Developer Could Be One of the Biggest Beneficiaries

As of December 31, 2022, the Zone 5 deposit at Khoemacau Copper Mining had a total mineral resource of approximately 92.9 million tonnes grading 2.0% copper and 21.3 grams per tonne silver.¹⁷  ‍

NEXM has already outlined over 24.7 Mt (Inferred) and 3 Mt (Indicated) of high-grade resources at Selebi,¹⁸ with aggressive expansion drilling underway to uncover new conductive targets even deeper and further along strike.

The company just completed a transformative $67 million recapitalization, erasing legacy debt and funding a full pivot to resource growth.¹⁹

Like Khoemacau before its breakout, NEXM is advancing ahead of the capital stampede now targeting critical minerals supply — not trailing behind it.

The difference?

Today, the world needs copper even more urgently than when Khoemacau started.

With a high-grade copper-nickel-cobalt resource and a refreshed balance sheet, NexMetals is shaping up to be one of the most strategic redevelopment stories in southern Africa.

Botswana has already proven it can deliver billion-dollar mining success stories.

MAJOR CATALYSTS TO RESEARCH

Copper is entering a full-blown supply crisis: The world is expected to need three times more copper by 2035, but major discoveries have collapsed by over 80% since 2010.²⁰ Prices are already pushing toward all-time highs — and the squeeze is just beginning.

Two past-producing, high-grade critical minerals mines: With a combined tonnage of 68.9 Mt (Inferred) and 3Mt (Indicated) between Selebi and Selkirk — and brownfield infrastructure and key permitting in place — NexMetals has a serious head start most juniors can only dream of.‍

High-grade expansion drilling is already underway: NEXM is aggressively targeting new conductive plates beyond the known deposits — including the untested hinge zone potentially connecting Selebi North and Main.

Fully recapitalized with strategic backing: Frank Giustra’s Fiore Management and EdgePoint Investment Group have repositioned NexMetals with minimal debt and the capital needed to drive near-term growth.

Located in one of the safest, mining-friendly jurisdictions on Earth: Botswana’s political stability, mining laws, and critical minerals focus make it the ideal jurisdiction — especially as political risk rises in Chile, Peru, and the DRC.

Early-mover advantage before a potential Nasdaq uplisting: Management has laid out a path toward a US uplisting — a move that could unlock a much broader investor base in 2025.²¹

Multiple catalysts in motion: Drill results, potential resource updates, metallurgical optimization and underground development progress all stack up to near-term news flow.

Key players are paying attention: NEXM not only offers similar jurisdictional advantages, brownfield upside, and expansion potential — but at an early valuation stage.

‍

NEWS

Jul 16, 2025

NexMetals Begins Trading on the Nasdaq Under the Symbol NEXM

Jul 9, 2025

NexMetals Accelerates Exploration Targeting High-Grade Mineralization Outside of Selkirk MRE Including 5.59% CuEq over 3.95 Metres Verified by Previous Reassay Program

Jun 30, 2025

NexMetals Drills 13.50 Metres of 3.68% CuEq Expanding Mineralization Significantly Below Selebi North Resource Footprint

Jun 24, 2025

NexMetals Accelerates Drilling at Selkirk Deposit by Adding Another Drill for Resource Expansion

Jun 18, 2025

NexMetals Hosts Investor Town Hall with Senior Leadership

Jun 18, 2025

NexMetals Announces Effective Date of Share Consolidation

Jun 16, 2025

NexMetals Appoints Former Lundin Mining Director Financial Reporting Brett MacKay as New Chief Financial Officer

Jun 11, 2025

NexMetals Commences Trading Under New Symbol “NEXM”

Jun 9, 2025

Premium Announces Name Change to NexMetals Mining Corp. and Changes Trading Symbol to NEXM

Jun 4, 2025

Premium Announces Results of Annual General and Special Shareholders’ Meeting

Jun 3, 2025

Premium Commences “Hinge” Drilling Targeting Large BHEM Plates in the 2km Area Between Selebi Deposits

May 27, 2025

Premium Drilling Extends Mineralization 315 Metres Below Resource Area Demonstrating Scaled Expansion at the Selebi Project

May 15, 2025

Premium Commences Resource Expansion Through Drilling and Comprehensive Metallurgy Optimization at Selkirk

May 8, 2025

Premium to Be Featured on Radius Research Webinar – Monday, May 12 – Register Now to Hear Directly from CEO Morgan Lekstrom

May 6, 2025

Premium Announces Intention to List on the NASDAQ and Provides Details for Upcoming Annual General & Special Meeting

May 1, 2025

Premium Drills Significant Mineralized Step-Out at Selebi North

Apr 24, 2025

Premium Appoints Mining Finance Executive and Former Gatos Silver CFO Andre van Niekerk to the Board

Apr 17, 2025

Premium Resources Infill Drilling at Selebi Delivers Grades Significantly Higher than Mineral Resource Estimate 27.55 Metres of 4.97% CuEq

Apr 10, 2025

Premium Resources High Impact Six Month Strategy Including Deep Drilling at Selebi

Mar 25, 2025

Premium Appoints Former Blackrock Senior Executive Chris Leavy to Board of Directors

Mar 18, 2025

Premium Resources Announces Closing of $46 Million Non-Brokered Equity Financing, Equity Conversion of $20.8 Million of Debt and New Strategic Advisors

Feb 20, 2025

Premium Resources Closes Book and Upsizes Non-Brokered Private Placement to C$44MM Due to Strong Demand

Feb 18, 2025

Premium Resources Announces New Strategic Investor Group, Non-Brokered Equity Financing of Up to C$36MM, Equity Settlement of C$20.8MM of Debt, and Leadership Change

Jan 27, 2025

Premium Resources Drills 14.20m of 5.14% CuEq or 2.49% NiEq Outside of Selebi North MRE and Provides Drilling Program Update

Jan 10, 2025

Premium Resources Files NI 43-101 Technical Report: Initial Mineral Resource Estimate of 44.2 MT for the Selkirk Mine in Botswana

Jan 10, 2025

Premium Resources Announces Quarterly Director DSU Grants

Management

Morgan Lekstrom

Chief Executive Officer & Director

Morgan Lekstrom

Mr. Lekstrom has over 17 years of experience in the mining industry, with a diverse background in executive and project management, operations, and engineering. He has an established track record of delivering successes, including most recently, the successful building of NexGold Mining Corp, creating a near term development company with a clear path to building two new Canadian gold mines. This was accomplished through deleveraging and restructuring debt, setting a new strategic direction for the company through multiple back-to-back mergers / acquisitions of Blackwolf Copper and Gold Ltd. and Treasury Metals Inc., and then Signal Gold Inc. in 2024.

He has also held senior technical roles with experience at Freeport McMoran’s Grasberg site in Indonesia and Rio Tinto’s Oyu Tolgoi Project in Mongolia. He has direct African experience through his role with Golden Star Resources in supporting the redevelopment of an underground mine in Ghana, West Africa. Morgan has also served as engineering manager at Sabina Gold & Silver Corp., where he was responsible for the first phases of execution at the Back River Marine Laydown Project.

Sean Whiteford

President

Sean Whiteford

Mr. Sean Whiteford is an accomplished geologist and mining executive with over 30 years of multi commodity experience within the global resource sector. He has extensive knowledge of mineral exploration, resource definition, mining, strategy, technology and project studies having held various corporate, operational and technical roles at BHP, Rio Tinto and Cliffs Natural Resource. Mr. Whiteford also has a strong business development background and has completed the Advanced Management Program from Columbia Business School. Most recently he was Vice President, Business Development at Burgundy Diamond Mines Ltd (ASX:BDM) and a Director of Premium Resources Ltd. He is a Member of the AUSIMM, PDAC, and SEG.

Brett MacKay

Senior Vice President & Chief Financial Officer

Brett MacKay

Brett MacKay is a seasoned finance executive with over 17 years of experience in the mining industry, most recently serving as the Company’s Vice President of Finance. Prior to joining the Company in October 2024, Brett held the role of Director of Financial Reporting at Lundin Mining Corporation. Throughout his 11 year tenure at Lundin, Brett led critical aspects of internal and external financial reporting, regulatory compliance, financial planning and analysis, treasury and cash management, systems strategy and implementation, and capital projects oversight, while managing global audits and supporting due diligence for international acquisitions. His leadership extended across operations in Brazil, Chile, and Argentina, where he played a pivotal role in integrating newly acquired assets into the broader corporate structure.

Brett is known for his strong technical accounting expertise and managing complex corporate structures across multiple jurisdictions. He has built and managed high-performing finance teams and worked directly with executive leadership to drive forecasting, budgeting, treasury operations, strategic financial planning, and robust project controls. His ability to translate complex financial data into meaningful insights has made him a trusted advisor in the mining sector. His proven track record in supporting growth-stage mining companies makes him a valuable addition to NexMetals as it advances toward development and long-term value creation.

Jaclyn Ruptash

Vice President Communications & Investor Relations

Jaclyn Ruptash

Jaclyn Ruptash has 20 years of domestic and international experience in the resources sector with an accomplished background in communications, corporate governance, legal and regulatory compliance, and financing.  Prior to joining NexMetals Mining Corp., Jaclyn held senior positions with several mining companies including with NexMetals Mining founding shareholder, formerly North American Nickel. She has been involved in all aspects of the operations with a variety of public and privately owned companies with direct responsibility for all continuous disclosure requirements, board and committee matters, corporate transactions, shareholder communications and corporate records. She has extensive experience in public and media relations, operations, and stakeholder communications.

Sharon Taylor, P. Geo.

Vice President Exploration

Sharon Taylor, P. Geo.

Ms. Sharon Taylor holds a B. Sc. from Mount Allison University and an M. Sc. from Queen’s University. She has over 35 years of experience in mineral exploration, including thirteen years with Falconbridge, Noranda, and Xstrata. She has experience in both volcanogenic massive sulfide and nickel exploration in major mining camps including Kidd Creek, Bathurst, Raglan, Sudbury and Kabanga. Her international exploration experience includes nickel projects in Tanzania and Greenland. Ms. Taylor’s area of expertise is the application and interpretation of EM data and integrating results from airborne, ground and downhole EM methods. 

Gerry Katchen, P. Geo

Exploration Manager

Gerry Katchen, P. Geo

Mr. Katchen has over 23 years of experience in mineral exploration and mining in North America Greenland, Finland, Tanzania and Botswana. Gerry obtained his B.Sc from Brandon University in 1998, and has since specialized in  the global exploration for Nickel, Copper and Platinum Group Metals hosted within intrusive Mafic/Ultramafic sulphide systems. 

Gerry’s former experience with North American Palladium, Placer Dome, Continental Nickel and as Exploration Manager for NEXM has provided a solid foundation in the systematic approach and application of shallow and deep exploration technologies and methods. His career highlights include the discovery of the Ntaka Hill Nickel-Copper Deposit in Tanzania for Continental Nickel and the PQ_Deeps discovery in Ontario, Canada for Placer Dome.

‍SINCERELY,

DISCLAIMER

[1] https://ici.radio-canada.ca/rci/en/news/2178155/trump-says-he-will-impose-50-tariff-on-copper [2] https://cdn.ihsmarkit.com/www/pdf/0722/The-Future-of-Copper_Full-Report_14July2022.pdf [3] https://aheadoftheherd.com/exposing-the-copper-surplus-myth-richard-mills/ [4] https://discoveryalert.com.au/news/copper-geopolitical-significance-2025/ [5] https://www.spglobal.com/market-intelligence/en/news-insights/research/from-6years-to-18years-the-increasing-trend-of-mine-lead-times [6] https://www.bhp.com/news/bhp-insights/2024/12/visualised-major-copper-discoveries-since-1900 [7] https://activeafrica.travel/destination/botswana/ [8] https://premiumresources.com/investors/news-releases/premium-nickel-files-ni-43-101-technical-report-i-9517/ [9] https://premiumresources.com/projects/botswana/selebi-mine/overview/ [10] https://premiumresources.com/investors/news-releases/premium-resources-announces-new-strategic-investor-9944/ [11] https://simplywall.st/stocks/us/materials/otc-prml.f/premium-resources/ownership [12] https://www.newsfilecorp.com/release/250953/Premium-Announces-Intention-to-List-on-the-NASDAQ-and-Provides-Details-for-Upcoming-Annual-General-Special-Meeting [13] https://premiumresources.com/projects/botswana/selebi-mine/overview/ [14] https://mininghalloffame.ca/frank-giustra-b-1957/ [15] https://mininghalloffame.ca/frank-giustra-b-1957/ [16] https://www.mining.com/web/mmg-to-invest-700-million-to-double-copper-output-at-botswana-mine [17] https://www.mccarthy.ca/en/work/cases/mmg-limited-completes-share-purchase-agreement-acquire-cuprous-capital-us188b [18] https://www.costmine.com/wp-content/uploads/2023/11/Khoemacau-2021-Maiden-Copper-Resource-Report-07-27-A.pdf [19] https://premiumresources.com/projects/botswana/selebi-mine/overview/ [20] https://www.tradingview.com/news/reuters.com,2025-04-22:newsml_TnwzR5XX:0-premium-resources-confirms-high-grade-copper-nickel-zone-in-botswana-begins-resource-expansion/ [21] https://aheadoftheherd.com/exposing-the-copper-surplus-myth-richard-mills/ [22] https://www.newsfilecorp.com/release/250953/Premium-Announces-Intention-to-List-on-the-NASDAQ-and-Provides-Details-for-Upcoming-Annual-General-Special-Meeting [23] https://premiumresources.com/investors/news-releases/premium-nickel-files-ni-43-101-technical-report-i-9517/ The MRE described in this news release has been reviewed and approved by Valerie Wilson, M.Sc., P.Geo. (Ontario) and a Principal Resource Geologist at SLR Consulting Ltd., who is independent of PNRL and a “qualified person” for purposes of NI 43-101. [24] https://www.costmine.com/wp-content/uploads/2023/11/Technical-Report-for-Selebi-Mines.pdf [25] https://paradigmcap.documents.streetcontxt.com/attachment/attachment%2FMTIwODY2ZTIxMmMyYmYwY2E1OWU3YzJjOTliN2NhOTg%3D.pdf?filename=UE5STCAtIFByZW1pdW0gTmlja2VsIC0gQm90c3dhbmEgLSBSZWp1dmVuYXRpbmcgSXRzIE5pY2tlbCBJbmR1c3RyeS5wZGY%3D [26] https://premiumresources.com/investors/news-releases/premium-nickel-files-ni-43-101-technical-report-i-9517/ [27] https://www.gurufocus.com/news/2786346/premium-resources-infill-drilling-at-selebi-delivers-grades-significantly-higher-than-mineral-resource-estimate-2755-metres-of-497-cueq-prmlf-stock-news [28] https://premiumresources.com/investors/news-releases/premium-resources-infill-drilling-at-selebi-delive-10052/ [29] https://www.juniorminingnetwork.com/junior-miner-news/press-releases/886-tsx-venture/prem/179314-premium-drills-significant-mineralized-step-out-at-selebi-north.html [30] https://nexmetalsmining.com/investors/news-releases/nexmetals-drills-13-50-metres-of-3-68-cueq-expand-10212/ [31] https://premiumresources.com/investors/news-releases/premium-nickel-files-ni-43-101-technical-report-i-9517/ The MRE described in this news release has been reviewed and approved by Valerie Wilson, M.Sc., P.Geo. (Ontario) and a Principal Resource Geologist at SLR Consulting Ltd., who is independent of PNRL and a “qualified person” for purposes of NI 43-101. [32] https://web.archive.org/web/20130705235906/http://www.nornik.ru/en/our_products/MineralReservesResourcesStatement/ [33] https://web.archive.org/web/20130705235906/http://www.nornik.ru/en/our_products/MineralReservesResourcesStatement/ NOTE: a qualified person has not done sufficient work to classify the historical estimate as current mineral resources or mineral reserves, and the Company is not treating the historical estimate as current mineral resources or mineral reserves. [34] https://premiumresources.com/site/assets/files/5686/selkirk_ni_43-101_mre_technical_report_nov_1_2024.pdf [35] https://premiumresources.com/site/assets/files/1/selkirk_ni_43-101_mre_technical_report_nov_1_2024.pdf [36] https://www.at-minerals.com/en/artikel/optimised-xrt-ore-sorting-solution-for-fine-particles-3951969.html [37] https://www.min-eng.com/physicalseparation24/drafts/session3/andrade.pdf [38] https://www.newsfilecorp.com/release/250953/Premium-Announces-Intention-to-List-on-the-NASDAQ-and-Provides-Details-for-Upcoming-Annual-General-Special-Meeting

‍THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.DISCLAIMER

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY NEXM AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

KSCP

***Sponsored by LFG Equities Corp

Knightscope Secures New 33,000 Sq Ft Silicon Valley Headquarters to Power Next Phase of Growth as a New Era Begins

________________________

‍Hello Everyone,

We have something exciting back on our radar ahead of Wednesday’s session. This is one that we haven’t looked at in quite some time. The last time we did it went on to double over the next few months after taking a bit of a dip. The last few weeks this one has been on the rampage.

Pull up KSCP immediately.

This AI robotics company is already on the move, literally.

With millions in revenue and over 4 million hours of autonomous operations, it’s been deployed coast-to-coast in government buildings, hospitals, airports, universities, and even law enforcement agencies.

The future isn’t coming. It’s already patrolling.

image1

Knightscope’s Explosive Growth: $5M+ in New Deals

Knightscope’s rise is unmistakable. Since April 2025, the company has clinched over $5 million in new contracts and renewals, proving that demand for its Autonomous Security Robots and Emergency Communication Devices is accelerating nationwide.

  • $2M+ in fresh sales and renewals across key sectors by early April.
  • $1.2M+ more from expanded government and enterprise agreements in late April.
  • $1M+ deal wins in June from new public and private sector projects.
  • $1M+ again in July with soaring bookings in emergency communications and robot deployments.

These are locked-in contracts and real deployments, not just prospects. Knightscope’s solutions are rolling out across cities, hospitals, and campuses as safety concerns and automation needs grow.

Accelerating Federal Traction

They’ve secured new government deals, highlighted by a Phase I contract with the U.S. Air Force via AFWERX to evaluate their security robots for military base protection. Knightscope’s first federal ASR installation launched at the Audie L. Murphy VA Medical Center, following full FedRAMP authorization, sets the stage for government adoption.

To fuel this, Knightscope has increased its activities in Washington DC both on Capitol Hill and the Pentagon connecting directly with potential key federal buyers.


Knightscope is pioneering the future of autonomous security, using Autonomous Security Robots (ASRs) and advanced Emergency Communication Devices (ECDs) to patrol public spaces, detect threats, and respond in real time – and are offered on a Machine-as-a-Service (MaaS) business model.

Knightscope’s K5 Autonomous Security Robot (ASR) is actively deployed at police departments as well as a variety of public and private properties such as storage facilities, casinos, hospitals, campuses, and commercial sites.

The K5 ASR is equipped with 360-degree, eye-level HD video, AI-driven anomaly detection, people and thermal detection, and license plate recognition for advanced, real-time security monitoring.

‍

As of July 2025, Knightscope’s market capitalization is approximately $51 million. While leading analysts, such as H.C. Wainwright, have issued bullish buy ratings and set aggressive price targets, we believe Knightscope’s true value is still flying under Wall Street’s radar.

Compared to its peers, the company stands out as a powerful, ground-floor opportunity that’s vastly undervalued. As momentum builds and more industry experts take notice, Knightscope is positioned to deliver potentially extraordinary long-term upside for early investors.

The Growth Curve Could Be Just Getting Started

If there’s one thing Wall Street consistently underestimates, it’s early-stage companies with real technology, real customers, and a recurring revenue model baked in from day one.

That’s exactly what we’re looking at with KSCP.

This isn’t some prototype company hoping to generate sales someday.

Knightscope is already in motion, earning revenue, scaling deployments, and building predictable income streams through its Machine-as-a-Service (MaaS) business model.

And yet…

The market is valuing it at under $51 million and Knightscope’s growth trajectory just got a major boost with the recent $1.7 million direct stock offering. This capital injection positions the company to scale its operations, advance its technology, and expand its footprint in the security robotics market.

That’s a rounding error compared to today’s AI titans. But it’s also where opportunity lives.

Just look at Nvidia (NASDAQ:NVDA). A decade ago, it was best known for gaming chips. Today? It’s the backbone of the AI revolution.

In just the past five years, NVDA stock surged more than 1,350% as investors caught on to its role in enabling next-gen intelligence.

Now ask yourself: What happens when the world catches up to the fact that Knightscope is doing for physical security what Nvidia did for AI computation?

In 2025 alone, KSCP:

  • Locked in over $5 million in new contracts, renewals and expansions
  • Expanded into universities, airports, and government agencies
  • Secured a new 33,000 sq ft Silicon Valley headquarters to support manufacturing, engineering, and deployment
image4

And this is just the start.

The broader trend is impossible to ignore.

In the US, there’s one human security officer for approximately 400 people. Labor shortages and rising costs are only compounding the problem. Meanwhile, crime and public safety concerns are escalating across the board.

That’s where KSCP steps in, offering round-the-clock AI protection, remotely managed, highly scalable, and now, federally certified.

As government contracts ramp up and private sector demand grows, Knightscope’s recurring revenue model could start compounding rapidly turning a tiny-cap robotics firm into one of the most important players in physical AI.

This isn’t theoretical anymore.

The infrastructure is built. The machines are online. And the revenue is already flowing.

KSCP is trading at a sub $51 million market cap with only 6.56 million shares outstanding.

That’s a tiny valuation and a low float for a company with:

  • Government clearance to operate across federal agencies (via FedRAMP ATO)
  • A partnership with Verizon Frontline to power real-time, first-responder-grade connectivity
  • A freshly inked contract with the U.S. Air Force15
  • A new 33,000 sq ft Silicon Valley headquarters built to scale operations nationwide
  • And a recurring revenue model through its Machine-as-a-Service (MaaS) platform; recurring revenue for the recurring societal problem of crime.

Insiders are aligned. CEO William Santana Li personally owns 223,924 shares, and institutional players like Vanguard, Geode Capital, and State Street are already on the books.

If you believe AI is transforming every corner of modern life from finance to medicine, ask yourself this:

Who’s leading the charge in physical security?

Knightscope may be the answer Wall Street hasn’t fully priced in… yet.


The Robots Are Coming To Washington And They’ve Got Clearance To Operate

When the U.S. federal government green-lights your tech for secure deployment across its agencies, it’s a signal worth paying attention to.


KSCP
 has earned that distinction.

Through the support of the U.S. Department of Veterans Affairs, Knightscope’s flagship K5 Autonomous Security Robot was awarded a FedRAMP Authority to Operate (ATO)17 — one of the most difficult certifications to achieve in the federal cybersecurity world.

Translation?

Knightscope’s AI-powered security systems are now approved for deployment across the entire U.S. federal government.

That alone could be a game-changer for this fast-moving robotics firm. Shortly after securing FedRAMP Authority to Operate, Knightscope reached a new level of federal credibility:

The U.S. Air Force selected Knightscope for a prestigious Phase I SBIR contract through AFWERX, its primary innovation arm. The initiative tasks Knightscope with evaluating and recommending upgrades for security protocols at Air Force installations nationwide.

Knightscope’s Autonomous Security Robots (ASRs) will be assessed for both perimeter and internal defense applications.

The project focuses on deploying robots equipped with real-time anomaly detection, 24/7 autonomous patrol capabilities, and advanced AI-driven threat analysis—features purpose-built to enhance base security and operational efficiency.

AFWERX isn’t just a collaborator; it’s the Department of the Air Force’s engine for bringing cutting-edge technologies into critical defense operations. Landing this contract marks a powerful endorsement of Knightscope’s tech and sets the stage for broader federal and military adoption

‍

image9

And behind it all is a powerful ally: Verizon.

Knightscope’s K5 GOV robots are deployed with priority access on Verizon’s Frontline network, giving them the same resilient, first-responder-grade connectivity relied on by emergency crews and public safety agencies across the country.

That means continuous surveillance, instant threat alerts, and one-touch access to fire, police, and EMS… even in mission-critical black zones.

This type of government-grade, always-on security solution couldn’t be more timely.

Demand for scalable, autonomous security is rising fast across the U.S. From schools and airports to transit hubs and federal sites, critical locations are actively searching for reliable, AI-powered solutions that don’t call in sick, take breaks, or miss a shift.

Knightscope, Inc. (NASDAQ:KSCP) is already trusted by institutions like:

  • The Port Authority of New York and New Jersey
  • Penn Entertainment
  • University in Tennessee

And recent traction backs it up.

Knightscope, Inc. (NASDAQ:KSCP) has:

  • Secured over $5 million in new business, including major client renewals and device expansions
  • Sold 70+ Emergency Communication Devices (ECDs) and six‑figure commitments for 11 Autonomous Security Robots (ASRs)
  • Reported a 4% YoY increase in service revenue, now totaling $7.5 million for FY 2024
  • Launched upgrades to the K5 ASR, improving its autonomous navigation and machine-learning threat detection

‍

Advanced Threat Detection

It’s not just federal agencies watching, Knightscope’s Automated Gunshot Detection pinpoints gunfire in real time and triggers alerts in as little as two seconds, helping first responders act fast when every moment counts. This rapid technology adds a crucial layer of protection for public spaces and organizations seeking cutting-edge safety solutions.


For a company still trading at small-cap levels, Knightscope’s growing presence in public safety, federal defense, and AI security infrastructure makes it one of the most overlooked stories in national tech.

And now that it’s got its clearance?

Expect the robots to keep marching.

Now, let’s take a look at some of the reasons KSCP is a force to be reckoned with in the public safety arena.

Knightscope Secures Another $1M in New Sales, Renewals & Expansions; Gains Momentum on Capitol Hill

PUBLISHED

JUL 2, 2025 9:35AM EDT

SUNNYVALE, Calif.–(BUSINESS WIRE)– Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, today announced over $1 million in newly secured contracts that span major client renewals, strategic expansions, and new wins across the country. The increase reflects a continuing demand for smarter, safer environments and is underscored by ongoing interest, including on Capitol Hill.

Emergency Communication Devices Grow Across the Nation

Knightscope locked in major new wins in the higher education, parks & recreation, healthcare, and local government sectors with an impressive 541 brand-new Emergency Communication Devices (ECDs) bookings. This wave of new contracts highlights the widespread trust in Knightscope’s life-saving communication technology.

Robots on Patrol: ASRs Hit New Markets

Knightscope’s Autonomous Security Robots (ASRs) are on the move. New K5 contracts are rolling out in the Transit Authority, Data Center, and Higher Education sectors, reinforcing its growing presence across critical infrastructure and public spaces.

Highlights at a Glance

  • Public Sector Power – Cities, states and law enforcement agencies are doubling down with expanded ECD purchases and extended Full-Service Maintenance (FSM) agreements.
  • Renewals Signal Results – Eight (8) ASR subscriptions were renewed across key sectors, including retail, biotech, and hospitality, proving Knightscope’s staying power and performance.

Capitol Hill

Knightscope continues to gain meaningful traction in Washington, D.C. Following recent visits that included dozens of engagements with public officials and stakeholders, the Company has been invited back for a hearing on certain technologies to occur in July.

Knightscope Exceeds $1M in Contracts in New Sales & Renewals

PUBLISHED

JUN 2, 2025 9:45AM EDT

SUNNYVALE, Calif.–(BUSINESS WIRE)– Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, today announced over $1 million in new contracts, including major client renewals, expanded service deployments, and new wins across the country.

The latest round of contracts includes resellers, higher education, transit authority, and local government clients placing orders for 525 Emergency Communication Devices (ECDs) and making six-figure commitments toward 7 Autonomous Security Robots (ASRs).

Recent Wins

  • Higher Education on the Rise – universities and colleges ramped up their campus safety efforts with orders for 118 new ECDs, further cementing Knightscope’s role as a campus security staple.
  • Commercial Real Estate Goes Autonomous – a top-tier property management firm added a K5 ASR and K1 Hemisphere units for around-the-clock patrols, real-time data feeds, and anomaly detection. They also subscribed to Risk & Threat Exposure (RTX) Analyst Premium Services to support multiple locations 24/7.
  • Public Sector Momentum Builds – municipalities, state agencies, airports, and law enforcement departments expanded their deployments with new ECD orders and extended Full-Service Maintenance (FSM) contracts.
  • Retention Reinforces Value – 13 ASR subscriptions were renewed across diverse industries, including biotech, hospitality, casinos and gaming, cosmetics and retail, validating the long-term ROI of Knightscope’s platform.

Fueling a High-Growth, Recurring Revenue Engine

Every new contract adds to Knightscope’s growing install base, reinforcing its leadership in AI-powered safety technologies. As public and private sector organizations seek smarter, more cost-effective solutions, Knightscope continues scaling a robust subscription-driven business model that delivers value well into the future.

‍

Management

image7

William Santana Li

Chairman And CEO

At 28, William Santana Li became the youngest senior executive at Ford Motor Company worldwide. With over 30 years of experience, he has a rich history in the global automotive industry and has founded and led multiple startups. At Ford, Li held various business and technical roles, including Director of Mergers & Acquisitions. He later secured $250 million in financing to found and serve as COO of GreenLeaf LLC, a Ford subsidiary. Li also founded Carbon Motors Corporation, focusing on developing the world’s first purpose-built law enforcement patrol vehicle.

image6

Mercedes Soria

EVP And Chief Intelligence Officer / CISO

With over 15 years of experience in systems development and software architecture, Soria is a technology professional who previously led IT strategy at Carbon Motors Corporation and is former Deloitte. Her expertise drives Knightscope’s intelligence and technological advancements.

image2

Apoorv S Dwivedi

EVP And Chief Financial Officer

Dwivedi brings extensive finance and corporate strategy experience. He served as CFO of Nxu, Inc. (NXU), leading it to a successful Nasdaq listing. His background includes key roles at Cox Automotive, Workiva, and General Electric, where he honed his skills in finance operations and corporate growth.

image8

Aaron J Lehnhardt

EVP And Chief Design Officer

Lehnhardt, Knightscope’s Chief Design Officer since 2015, previously led design at California Motors and co-owned Lehnhardt Creative LLC. His work spans advanced vehicle design, military projects, and innovative personal mobility solutions.

‍

NEWS

Knightscope Secures Another $1M in New Sales, Renewals & Expansions; Gains Momentum on Capitol Hill

Jul 2, 2025

Knightscope Exceeds $1M in Contracts in New Sales & Renewals

Jun 2, 2025

Knightscope Reports First Quarter 2025 Financial Results

May 14, 2025

Knightscope Joins AUVSI to Advance Autonomous Systems Policy

May 9, 2025

Knightscope Secures $1.2+ Million Boost in Sales Won and Client Base Growth

Apr 24, 2025

Knightscope Secures New 33,000 Sq Ft Silicon Valley Headquarters to Power Next Phase of Growth as a New Era Begins

Apr 10, 2025

Knightscope Surges with $2+ Million in Sales, Renewals and Expansions

Apr 3, 2025

Knightscope Reports FY 2024 Results

Mar 31, 2025

Knightscope Closes $1.7 Million Registered Direct Offering of Common Stock

Mar 31, 2025

Knightscope Announces $1.7 Million Registered Direct Offering of Common Stock

Mar 28, 2025

Knightscope and Alliance Entertainment Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mar 21, 2025

Knightscope Submits AI Recommendations to White House

Mar 18, 2025

On the Move: 107 Knightscope Machines & Devices

Mar 10, 2025

Knightscope Gains Momentum: Sales, Expansion and Upgrades Continue

Feb 20, 2025

Knightscope Expands Presence in Healthcare and Launches Robot Quiz

Feb 12, 2025

Knightscope Secures Over $1M in Annual Recurring Revenue through Renewals

Feb 10, 2025

Knightscope Establishes Federal Presence, Robots Headed to Washington D.C.

Feb 6, 2025

Knightscope Achieves Full FedRAMP® Authorization, Unlocking Federal Growth

Feb 4, 2025

H.C. Wainwright Initiates Coverage on Knightscope (NASDAQ: KSCP) with a Buy Rating and $16 Price Target

Jan 31, 2025

Knightscope Partners with U.S. Air Force on Autonomous Security Robots

Jan 28, 2025

‍SINCERELY,

DISCLAIMER

  1. https://ir.knightscope.com/ – Corporate Deck
  2. https://api-dev.kscope.io/ks-doc-view?key=c7709e09-05a9-430e-b23b-14f263a732ad&content=benznews&docid=aabb4343ae423405fd3ff59e24f7ad8d6db2ecdf
  3. https://api-dev.kscope.io/ks-doc-view?key=c7709e09-05a9-430e-b23b-14f263a732ad&content=benznews&docid=1b5be8dc3509be4b83b16550eef5ffa5825d8235
  4. https://api-dev.kscope.io/ks-doc-view?key=c7709e09-05a9-430e-b23b-14f263a732ad&content=benznews&docid=0f03ae1d574c57d60acdb53f85e037d1faff1cd3
  5. https://api-dev.kscope.io/ks-doc-view?key=c7709e09-05a9-430e-b23b-14f263a732ad&content=benznews&docid=47a8cba6dfb78eb687d4d98ced505bc86de3f549
  6. https://finance.yahoo.com/news/knightscope-partners-u-air-force-143500656.html
  7. https://finance.yahoo.com/news/knightscope-establishes-federal-presence-robots-144000374.html
  8. https://www.businesswire.com/news/home/20250131538787/en/H.C.-Wainwright-Initiates-Coverage-on-Knightscope-NASDAQ-KSCP-with-a-Buy-Rating-and-%2416-Price-Target
  9. https://api-dev.kscope.io/ks-doc-view?key=c7709e09-05a9-430e-b23b-14f263a732ad&content=benznews&docid=1dca61be23589df0e21082144e89f9c0f1c2364
  10. https://api-dev.kscope.io/ks-doc-view?key=c7709e09-05a9-430e-b23b-14f263a732ad&content=benznews&docid=a39fdd9ca36bcbed6d397f572c17288115f2057f
  11. https://ca.finance.yahoo.com/quote/KSCP/key-statistics/
  12. https://www.verizon.com/about/news/verizon-partners-knightscope-public-safety-tech
  13. https://www.secform4.com/insider-holders/1600983.html
  14. https://ca.finance.yahoo.com/quote/KSCP/holders/
  15. https://www.businesswire.com/news/home/20241008591877/en/FDNY-and-PANYNJ-Expand-Emergency-Communication-Contracts
  1. https://finance.yahoo.com/news/exclusive-knightscope-penn-entertainment-join-152207734.html
  2. https://www.tsandl.us/press-release/boca-raton-florida–read-all-about-it-the-university-of-tennessee-selects-ts-l-to-supply-and-integrate-knightscope-k1-blue-light-towers?4d5aebda_page=5&7d41c26a_page=1
  3. https://www.businesswire.com/news/home/20250424652862/en/Knightscope-Secures-$1.2-Million-Boost-in-Sales-Won-and-Client-Base-Growth
  4. https://www.businesswire.com/news/home/20250331191777/en/Knightscope-Reports-FY-2024-Results
  5. https://www.businesswire.com/news/home/20250123845732/en/Knightscope-K5-Upgrade-Expands-Market-Reach
  6. https://www.businesswire.com/news/home/20231129468651/en/Knightscope-Begins-Selling-Automated-Gunshot-Detection

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.DISCLAIMER

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND ONE HUNDRED TWENTY FIVE USD BY LFG EQUITIES CORP FOR A ONE DAY KSCP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

SRFM

***Sponsored by LFG Equities Corp.

They have exclusive agreements with multi-billion dollar market cap company Textron Aviation (NYSE:TXT), one of the world’s largest general aviation manufacturers and a strategic relationship with Palantir Technologies (NASDAQ:PLTR), leveraging cutting-edge AI and data analytics

CHECK OUT THE MOST RECENT INVESTOR PRESENTATION HERE

_______________________

Hello Everyone,

We have something back on our radar ahead of Tuesday’s session that you are going to want to research. That is if you aren’t already watching this one from early June when we brought it to your attention and told you to research it. It was sitting at just over 2 bucks back then.

Well it just hit $9.91 on Friday. That’s an almost 500%+ move in a little over a month’s time. It closed green 6 sessions in a row before Monday’s session.

What we saw today was a healthy pullback. This one is up so much in the past month that we saw some profit taking and potentially some shorting during Monday’s session. We want to take another look at this one with all of its momentum.

A Quick Look at this company and you can’t help but draw comparisons to corporate giants Uber and Lyft.

The main difference is that SRFM is doing it IN THE AIR and there certainly seems to be demand for it.

Putting the infrastructure in place for something like this is no easy task. That is why they inked an agreement with AI Blue Chip, Palantir.

Unlike others in the space, Surf Air Mobility isn’t just a concept—it’s a fully operational business generating real revenue and focused on leading the charge in transforming regional air mobility.

The company and business model has even caught the eye of AI Giant Palantir. They have a stake of 4.46 million shares in the company as of April. I know “Smart Money” is an objective term but I will go ahead and assume that Palantir has done their research.

Surf Air Mobility is a Los Angeles-based regional air mobility platform expanding the category of regional air travel to transform flying through the power of electrification and software. In an effort to substantially reduce the cost and environmental impact of flying and as the owner of one of the largest commuter airlines in the US, Surf Air Mobility intends to develop powertrain technology with its commercial partners to electrify existing fleets and bring electrified aircraft to market at scale. The management team has deep experience and expertise across aviation, electrification, and consumer technology.

A lot has happened with the company since the last time we put it in front of you.

Most recently we saw the chairman and also one of the co-founders put their money where their mouth is. Using our last profile on SRFM back in August as a benchmark, you can see that as of late, management has the company heading in the right direction.

The company has been taking some serious steps towards their transformation plan.

  • Relocated their Air Operations Center to Addison, Texas, a suburb of Dallas—placing them in the heart of one of America’s top aviation talent hubs.
  • Hired elite leadership from Southwest Airlines, Hawaiian Airlines, Amazon Air, Flexjet, and Bombardier to run operations with military-level efficiency.
  • Delivered four brand-new Cessna Grand Caravan EX aircraft from Textron Aviation to refresh their fleet and prep for future electric upgrades.

And they’re not stopping there.

In 2025, Surf Air (NYSE:SRFM) plans to:

  • Achieve profitability in airline operations (defined by positive adjusted EBITDA) this year
  • Roll out SurfOS to more third-party users, with the potential to open a new high-margin software revenue stream

On top of that, they’re working to create a new venture called Surf Air Technologies—a dedicated venture focused on commercializing SurfOS. The company has even stated it’s considering bringing in outside investors to fund this separately.

Internationally, MOUs are already in place to electrify commuter fleets in Brazil and Kenya once the technology is certified—opening up first-mover advantages in emerging markets where regional air travel is essential.

And with new FAA subsidies approved by Congress in 2024, providing potential tailwinds to Surf Air’s subsidized essential air routes via its airline subbrands, Southern Airways and Mokulele Airlines.

This is key—because while rivals are still trying to certify futuristic prototypes…

Surf Air Mobility (NYSE:SRFM) is already embedding itself into the backbone of regional air infrastructure.

This isn’t a long-term science experiment.

This is a near-term commercial story with real milestones.

Surf Air Mobility Announces $1 Million Purchase of Company Stock by Co-Founder

MAY 28, 2025

Co-Founder and Member of the Board, Sudhin Shahani, purchased over 400,000 shares of Surf Air Mobility Inc. Common stock at market price

LOS ANGELES–(BUSINESS WIRE)– Surf Air Mobility Inc. (NYSE: SRFM) (“the Company”, “Surf Air Mobility”), a leading regional air mobility platform, announced that Co-Founder and Member of the Board, Sudhin Shahani, purchased 408,163 shares of the Company’s common stock at the market price, for a purchase price of approximately $1 million, directly from the Company in a private transaction.

Mr. Shahani said: “Our Transformation Plan is already having an early impact. We’ve improved operations and strengthened the core business. I’m confident in our experienced leadership team’s continued execution capabilities.”

The Company remains focused on the Optimization Phase of the Transformation Plan with key initiatives to optimize airline operations, recalibrate the On Demand business, and drive efficiencies from SurfOS.

Top Reasons to Research This One

  1. A Massive Growth Market: By 2035, the total addressable market (TAM) for small regional flights globally could reach $75 billion to $115 billion by 2035
  2. One of The Largest Commuter Airlines in the US: Surf Air Mobility Inc. (NYSE:SRFM) is one of the leaders in the nation with the most scheduled departures, carrying over 330,000 passengers on 66,000 flights in the last 12 months ending March 31, 2025.
  3. Impressive Revenue Performance: The company generated ~$112M in revenue in the last 12 months ending March 31, 2025.
  4. Powerful Commercial Relationships: Strategic alliances with industry leaders like Palantir Technologies and Textron Aviation bolster Surf Air’s competitive edge across the value chain.
  5. Seasoned Leadership Team: A management team with extensive experience, including past leadership roles at Bombardier Flexjet, United, and Wisk, is driving the company forward.
  6. Multi-Phased Transformation Plan: Backed by a cumulative ~$82 million from recent financings, SRFM is executing a four-phase transformation plan designed to optimize its airline operations and put them on a path to profitability, broadly offer its SurfOS software, expand routes, and create a platform for new electrification technology in the future.
  7. Game-Changing Collaboration: The recent agreement with a leading tech giant is a significant step forward for Surf Air Mobility. By harnessing Palantir’s cutting-edge AI and data analytics platforms, this collaboration will enable the company to deliver unparalleled operational efficiencies, setting a new standard in the air mobility market.
  8. Pioneering Sustainable Aviation: Surf Air Mobility is not only focused on improving operational efficiency but also on sustainability. By developing powertrain technology to electrify smaller existing aircraft, the company is taking significant steps toward decarbonizing air travel once certified. Imagine a future where flying between 50 to 500 miles is not only eco-friendly but also cost-effective—a vision that Surf Air Mobility is actively working to make a reality for itself and others.
  9. Strategic Partnerships and Global Reach: Surf Air Mobility continues to expand its global footprint through strategic deals in places like East Africa and Brazil.

Surf Air Mobility Unveils Four-Phase Transformation Plan

2024

PHASE 1: TRANSFORMATION | COMPLETE

The first phase of the Transformation Plan is now complete. The Transformation phase was centered around four key initiatives: 1) improving the company’s capital structure, 2) strengthening the company’s balance sheet, 3) appointing the right management team, and 4) realizing M&A synergies from the company’s merger with Southern Airways.

Surf Air Mobility addressed these key initiatives in the following ways: 1) improved its capital structure by securing $50 million in funding and extended the maturities of other secured debt until December 31, 2028, 2) strengthened its balance sheet by addressing past liabilities totaling approximately $70 million with an expected target reduction of greater than 50%, 3) hired and promoted leaders with decades of aviation experience across the organization, and 4) realized M&A synergies totaling approximately $6.5 million.

2025-2026

PHASE 2: OPTIMIZATION

Surf Air is now in the second phase of its Transformation Plan: Optimization. This phase of the plan is focused on maximizing the profitability of the company’s scheduled service and On Demand charter operations.

As part of scheduled service optimization, the company is implementing systems and processes to measure and drive efficiencies against real-time operational and financial KPIs. The company is also addressing its deferred maintenance backlog to improve aircraft availability and flight completion rates. In parallel, the company is exiting unprofitable routes and redeploying aircraft. Through this reallocation of aircraft assets, Surf Air is calibrating the timing of its purchases of new aircraft to match the timing of its route expansion phase in 2026 and 2027. As a result of these initiatives, management expects its airline operations to become profitable in FY 2025, as defined as positive Adjusted EBITDA.

As part of the recalibration of its On Demand business, Surf Air’s go-forward strategy focuses on expanding market share in the higher margin jet category, securing inventory through advance volume purchase agreements and pursuing international partnerships. These efforts are designed to drive revenue growth and profitability in the On Demand business over time.

Finally, the company anticipates that further implementation of its SurfOS software solutions, which it is developing with Palantir, will continue throughout the Optimization phase to drive productivity and efficiency improvements across the organization.

2026-2027

PHASE 3: EXPANSION

Surf Air Mobility anticipates entering the third phase of its Transformation Plan, Expansion, in FY 2026. During this phase, the company will profitably expand its network by launching new tier-1 routes in regions across the U.S., using data-driven insights to quantify and qualify route attractiveness. As a base case, tier-1 routes will be selected for profitability using current combustion aircraft with further margin improvements anticipated once electrified planes are commercialized.

Alongside this network expansion, Surf Air anticipates pursuing additional venture opportunities that leverage the company’s scale, to separately capitalize high-growth initiatives with strategic partners.

During the Expansion phase, SurfOS will be broadly marketed to third-party customers (including air operators, charter brokers, and aviation OEMs) through the Surf Air Technologies venture entity developing an operating system powered by Palantir, and will begin to develop revenue traction. As one of the largest commuter airlines in the U.S. by scheduled departures, Surf Air Mobility is uniquely positioned to develop, test, and deploy software solutions that will power the emergence and growth of the Regional Air Mobility segment, which McKinsey & Co. estimates will grow to between $75 billion and $115 billion globally by 2035.

2027+

PHASE 4: ACCELERATION

The company anticipates entering the last phase of its Transformation Plan, Acceleration, in FY 2027. During this phase, Surf Air plans to spur revenue growth and margin expansion by leveraging its air mobility platform to accelerate the adoption of new aviation technologies–its own and that of others–and leverage the network effects of its operator platform to emerge as a category leader.

A key focus of the Acceleration phase is the certification of the company’s proprietary electrified powertrain technology for the Cessna Grand Caravan, which Surf Air currently anticipates will occur within the framework of a joint venture with a leading industry partner. Post-certification of its electrified powertrain technology, Surf Air will leverage its exclusive sales and marketing relationship with Textron Aviation, a leading general aviation manufacturer and Cessna owner, to commercialize these powertrains.

Surf Air Mobility Introduces Flagship SurfOS™ AI-Enabled Product Suite for Air Mobility Industry

JUN 10, 2025 6:30AM EDT

Unveils BrokerOS, OperatorOS, and OwnerOS: a unified, AI-enabled software platform to make the Air Mobility industry more efficient, reliable, and profitable.

Software tools are being designed to serve the current regional aviation industry while laying the foundation for the future Air Mobility customer landscape.

LOS ANGELES–(BUSINESS WIRE)– Surf Air Mobility Inc. (NYSE: SRFM) (“the Company”, “Surf Air Mobility”), a leading regional air mobility platform, today unveiled the three flagship software products of the Company’s SurfOS AI-enabled operating system scheduled for broad commercial release in 2026. BrokerOS, OperatorOS, and OwnerOS are purpose-built to address the needs of charter brokers, aircraft operators, and aircraft owners, respectively.

SurfOS will integrate industry data into a single, federated platform, creating an operating system for the Regional Air Mobility industry powered by Palantir Technologies (NASDAQ: PLTR).

Deanna White, CEO and COO of Surf Air Mobility, said: “From crew scheduling to flight planning to sourcing on-demand charter aircraft, SurfOS is helping our teams work smarter every day. As we roll out more SurfOS tools internally, we will continue to automate manual tasks and improve reliability to ensure our aircraft and crews are operating as efficiently as possible.”

Sudhin Shahani, Co-founder of Surf Air Mobility, said: “We’re creating an operating system that unifies industry data to improve efficiency and increase profitability. Our software will not only serve today’s regional and private aviation stakeholders, but is also being built in anticipation of the rapidly approaching era of electrified aircraft. These new electrified aircraft operators will need modern software to manage flight operations and consumer distribution.”

SurfOS flagship products:

BrokerOS consists of software tools specifically tailored for charter brokers. BrokerOS software tools streamline sourcing, quoting, booking, and payments for charter brokers. These tools will reduce manual workflows and will give both new and experienced brokers instant access to available inventory, live pricing, and end-to-end trip management capabilities.

BrokerOS is currently being used to manage the Company’s Surf On Demand charter service and, once commercially available, will target the hundreds of Part 295 private charter broker companies and thousands of travel agents worldwide.

OperatorOS consists of software tools specifically tailored for aircraft operators. OperatorOS software tools are designed to optimize aircraft and crew scheduling for both Part 135 charter operators and scheduled commuter airlines. Leveraging these tools, operators can reduce turn times and improve aircraft and pilot utilization by tapping into operational data and automated crew planning. OperatorOS also includes a companion mobile Crew App, currently used by the Company today, that enables flight crews to check in for duty and receive flight schedules and operational updates to streamline day-of-flight coordination.

Once commercially available, OperatorOS will target the 1,800+ Part 135 operators, of which the Company’s commuter airline, Southern Airways, is one of the largest in the U.S. by scheduled departures.

OwnerOS consists of software tools specifically tailored for aircraft owners. OwnerOS software tools are designed to deliver transparency and optimization capabilities to private aircraft owners. Through a native integration with OperatorOS, private aircraft owners will gain insight and better visibility into how their assets are being used as well as an interface to support decisions that optimize aircraft utilization to generate better returns on assets.

Once commercially available, OwnerOS will target the owners of the 11.7K+ Part 135 aircraft in use today.

SurfOS currently has beta agreements with eight users that are helping shape the development of key BrokerOS and OperatorOS features.

While SurfOS is positioned to serve the Regional Air Mobility industry, which is projected to be $75–$115 billion globally by 2035, the first commercial software products will have a more immediate impact on today’s private aviation landscape. BrokerOS and OperatorOS are designed to address the global private jet charter services market, an estimated $41 billion opportunity by 2029, while OwnerOS is designed to address the estimated $40 billion global private aircraft sales market.

Revenue Streams

SRFM is revamping travel. They’re not just changing the game; they’re rewriting the playbook with a diverse revenue mix.

Their role in essential air services (EAS) adds consistent, subsidized revenue.

SRFM has a multi-pronged strategy to transform the skies:

  • Acquisition of Southern Airlines jumpstarted operations, deploying a fleet of ~50 aircraft on a nationwide network of flights.
  • Agreement with Textron Aviation for new Cessna Grand Caravan EX models

SRFM has begun making waves in East Africa and Brazil, sealing strategic MOU agreements with air operators to electrify their fleets once the technology is certified.

In a groundbreaking move, Surf Air Mobility has announced MOU agreements with some of Kenya’s premier safari air services, Safarilink,Yellow Wings Air, and Z.Boskovic to electrify their fleets.

By upgrading existing Cessna Grand Caravan aircraft fleets with SRFM cutting-edge electrified powertrain technology, they could revolutionize air travel in Kenya and beyond.

This initiative builds upon Surf Air Mobility’s earlier collaboration with Azul, Brazil’s largest airline, to electrify up to 27 of its Cessna Caravans.

With targets of reducing direct operating costs by up to 50% and eliminating 100% of direct carbon emissions on fully electric versions of the powertrain, Surf Air Mobility Inc. (NYSE:SRFM) plans to propel the industry towards a greener, more efficient future in regional air travel.

Surf Air Mobility Reports Key Achievements in Optimization Phase of Transformation Plan

Company has achieved record-high scheduled airline reliability.

LOS ANGELES–(BUSINESS WIRE)– Surf Air Mobility Inc. (NYSE: SRFM) (“the Company”, “Surf Air Mobility”), a leading regional air mobility platform, today announced key progress within the second phase of the Company’s four-phase Transformation Plan. The Optimization phase is focused on operational improvements and internal SurfOS™ technology deployment to achieve profitability in the Company’s airline operations this year, defined as positive Adjusted EBITDA.

Recent Optimization phase key achievements include:

Optimize airline operations (Southern Airways and Mokulele Airlines)

  • Steadily improved controllable completion factor over the past several months with an increase of 10% compared to FY24.
  • Steadily improved D0 (on time departures) over the past several months with an increase of 21% compared to FY24.
  • Steadily improved A14 (arrivals within 14 minutes of planned schedule) over the past several months with an increase of 21% compared to FY24.
  • Recently won a bid contract renewal in one Essential Air Service community, resulting in ~$9.9 million of additional subsidy revenue over the next 4 years.

Controllable completion factor, D0, and A14, are currently the highest on record since January 2023, and the Company believes the continued improvements to operational reliability will further strengthen customer satisfaction and position the airline for long-term, profitable growth.

Recalibrate the On Demand business

  • The Surf On Demand business has now worked with over 425 operators since inception.

Drive efficiencies from SurfOS

  • Pilot reporting for non-regulatory filings of Flight Risk Assessment Tool (FRAT) reports have doubled since the launch of the Company’s Crew App, strengthening its safety culture, enhancing its operational visibility, and enabling proactive risk mitigation.

The company attributes much of the operational improvement to steps taken by its strengthened senior leadership team with talent from Southwest, Flexjet, and Amazon Air, as well as the significant investments made in refurbishing aircraft, introducing new Cessna Caravans into service, and the broadening internal adoption of SurfOS.

Deanna White, CEO and COO of Surf Air Mobility, said: “The primary objective of the Optimization phase of our Transformation Plan is to build a more efficient and profitable organization to set the foundation from which to expand our network and accelerate our growth. These recent results illustrate the impact of the significant investments we’ve made across the organization and within our fleet. These improved metrics reflect a tangible return on investment and highlight the results and execution momentum of our Transformation Plan.”

Surf Air Mobility remains on track to enter the third phase of the company’s Transformation Plan, “Expansion,” in 2026, within which the Company plans to launch new scheduled routes and offer SurfOS to third-party customers.

‍

NEWS

Surf Air Mobility to Present at the Emerging Growth Conference

4 days ago

Surf Air Mobility Announces $27 Million Registered Direct Offering of Common Stock

Jun 25, 2025

Surf Air Mobility Reports Key Achievements in Optimization Phase of Transformation Plan

Jun 17, 2025

Surf Air Mobility Introduces Flagship SurfOS™ AI-Enabled Product Suite for Air Mobility Industry

Jun 10, 2025

Surf Air Mobility Announces $1 Million Purchase of Company Stock by Co-Founder

May 28, 2025

Stonegate Capital Partners Updates Coverage on Surf Air Mobility Inc. (SRFM) 2025 Q1

May 15, 2025

Surf Air Mobility to Present at the Third Annual Jefferies eVTOL / AAM Summit

May 14, 2025

Surf Air Mobility Reports First Quarter 2025 Financial Results

May 13, 2025

Mokulele Airlines and Japan Airlines Announce New Interline Agreement

May 6, 2025

Surf Air Mobility to Announce First Quarter 2025 Financial Results on May 13, 2025

May 2, 2025

Surf Air Mobility Closes $5 Million Registered Direct Offering of Common Stock

Apr 1, 2025

Surf Air Mobility Announces $5 Million Registered Direct Offering of Common Stock

Mar 31, 2025

Stonegate Capital Partners Initiates Coverage on Surf Air Mobility Inc. (SRFM)

Mar 24, 2025

Surf Air Mobility Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 18, 2025

Surf Air Mobility to Announce Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Mar 6, 2025

Surf Air Mobility Announces Launch Customers for SurfOS™ Software

Mar 4, 2025

Surf Air Mobility Strengthens Aviation Leadership Team with Key Executive Appointments

Mar 3, 2025

Surf Air Mobility Relocates Air Operations Center to Addison, TX

Feb 25, 2025

Surf Air Mobility Publishes Video on Air Mobility Business

Feb 14, 2025

Surf Air Mobility Publishes Video on Company’s Strategy, Transformation Plan and Growth Opportunities

Jan 29, 2025

Surf Air Mobility Announces Open Market Purchases of Company Stock by Board Members

Dec 27, 2024

Surf Air Mobility Appoints David Anderman to Board of Directors

Dec 19, 2024

Surf Air Mobility Announces Approximately 90% Reduction to Contemplated Future Equity Dilution

Dec 12, 2024

Deanna White Appointed as Surf Air Mobility’s Chief Executive Officer

Dec 10, 2024

‍

MANAGEMENT TEAM

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND EIGHT HUNDRED FIFTY USD BY LFG EQUITIES CORP FOR A ONE DAY SRFM AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

BSGM Nasdaq

***Sponsored by LFG Equities Corp.

BioSig Technologies, Inc.

BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1.1B USD in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Markets

Hello Everyone,

We have something back on our radar that we need to research ahead of Friday’s open.

We took a look at this one a little over a month ago when it opened at 6.11 and hit highs of 8.80 that same session. It was a huge winner for us…. but the story gets better. Just days ago it hit 14.11 on huge interest.

It has pulled back over the past few days and is right back in the channel it was in before the algorithms took over and it exploded.

Pull up BSGM immediately.

You might be familiar with this one.  We took a look at it a few years back quite a few times.  

A lot has changed with BSGM since we first started looking at it years back.  

Fortunately the change took place just last month so we are at the forefront of the news and the merger.

BSGM just announced the completion of a share exchange agreement with Streamex, a real-world asset (RWA) tokenization company focused in the commodities space.

Look at this Chart! Since July 1st we have seen some volatility. It started out at 7 bucks and closed green 4 sessions in a row. By July 8th this thing destroyed resistance and breached 14 bucks for a 100% move. We have seen the expected profit taking over the past 4 sessions that has brought it back to the level where we feel it is time to take another look at this one.

BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1.1B USD in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Markets

PUBLISHED

JUL 7, 2025 6:41PM EDT

  • BioSig Technologies, Inc. (Nasdaq: BSGM), which recently merged with Streamex Exchange Corporation (“Streamex”) to become one of largest public holders of gold bullion.
  • Streamex’ proprietary real-world asset (the “RWA”) platform will bring the approx. $142 trillion commodities market on the blockchain powered by Streamex & Solana.
  • The transaction was led by:
    • Cantor Fitzgerald & Co., Clear Street LLC and Needham & Company, LLC acting as placement agents; and
    • CIBC World Markets acting as Strategic Advisor to the BSGM board of directors and management.

VANCOUVER, British Columbia & LOS ANGELES–(BUSINESS WIRE)– BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (Nasdaq: BSGM), announced today that the Company has entered into definitive agreements with a leading institutional investor for up to US$1.1 billion in growth financing, positioning the Company to become one of Nasdaq’s largest public holders of gold bullion. This transaction positions the Company to capitalize on its goal of reshaping the future of global finance by beginning to bring the approx. $142 trillioncommodities market on chain through real world asset tokenization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707385647/en/

Streamex & BioSig signed a definitive agreement for the sale of US$100,000,000 in senior secured convertible debentures and a US$1,000,000,000 Equity Line of Credit. The debentures have a maturity date of 24 months after issuance, accrue interest at 4% per annum, which will increase to 18% per annum upon the occurrence of an event of default, until such event of default is cured. The debentures will be purchased at a purchase price of 96% of their principal amounts. The debentures are convertible into shares of the Company’s common stock, and the Company and certain of its subsidiaries are granting a first priority lien on and security interest in some of their respective assets as security for the Company’s obligations under the debentures. Under the equity line of credit, the Company has the right, but not the obligation, to sell common stock to the investor for up to $1,000,000,000 over 36 months. The Company has agreed to file a registration statement with the Securities and Exchange Commission to register the shares of common stock that are issuable upon conversion of the debentures and that may be sold under the equity line of credit (the “Resale Registration Statement”).

The offering of US$75 million in senior secured convertible debentures and the equity line of credit is expected to close on or about October 7, 2025, subject to obtaining certain approvals of the Company’s shareholders as required by Nasdaq listing rules, and to other customary closing conditions. The remaining US$25 million in senior secured convertible debentures is expected to close subject to obtaining certain closing conditions, including the effectiveness of the Resale Registration Statement. The Company believes that this transaction will secure its position as a gold treasury company and anticipates a continued investment in RWA blockchain technology. The Company looks ahead to securing substantial financial flexibility and seizing opportunities within its core markets.

Cantor Fitzgerald & Co., and Clear Street LLC acted as co-lead placement agents, with Needham & Company, LLC acting as co-placement agents (collectively, the “Placement Agents”). CIBC World Markets acted as financial advisor to the BioSig board of directors and management. Sichenzia Ross Ference Carmel LLP is serving as legal counsel to the Company. Reed Smith LLP is serving as legal counsel to the Placement Agents.

BioSig CEO and Streamex Co-Founder Henry McPhie, says, “This financing marks a pivotal moment not only for Streamex and BioSig, but for the evolution of global financial markets. By combining the value of physical gold with the innovation of blockchain, we are building a company grounded in what we believe to be the world’s most trusted store of value while enabling a scalable, high-return business model through tokenization. Our mission is to unlock liquidity, transparency, and accessibility across the $142 trillion commodities market, and this milestone is just the beginning.”

Co-Founder of Streamex and Chairman of BioSig, Morgan Lekstrom added, “The on-chain integration of gold and commodities represents a transformative evolution in global finance. While many treasury models exist, the approach pioneered by Streamex and BioSigcombining physical gold with a scalable, revenue-generating tokenization platform introduces an entirely new value proposition for token holders. This is a landmark innovation, and we are committed to demonstrating to the market and our shareholders the full potential of this platform to redefine how real-world assets are accessed, valued, and monetized.”

Streamex believes RWA tokenization, and gold tokenization especially, will be more important than Bitcoin, driven by positive gold price outlook and anticipated rapid adoption of tokenization of RWAs by traditional financial institutions. Daily trading volume in gold bullion is $233 billion, 4.5 times greater than the $55 billion daily trading volume of Bitcoin, according to the World Gold Council, and the total market for gold is over 11x larger. The total addressable market (TAM) for RWA tokenization is projected to reach $16 trillion by 2030, according to global consulting firm Boston Consulting Group and ADDX, the digital exchange for private markets. Streamex is uniquely positioned as a first mover in the commodities and $22 trillion gold market.

The Company intends to hold significant quantities of gold bullion, secured through allocated vaulting with a top-tier bullion bank, with denominating the majority of its balance sheet in vaulted physical gold rather than fiat currency. Streamex believes that combining gold holdings with its Solana blockchain-enabled tokenization technology will support a scalable recurring revenue model and drive attractive returns. The Company’s integrated technology platform and gold-backed balance sheet are expected to position it strongly to fund and issue a variety of gold-related tokens. These tokens aim to provide efficient, low-cost access to gold investments while also supporting gold-related financing structures, offering the potential for returns that outperform traditional bullion holdings.

Strategic Advisor and mining financier Frank Giustra stated, “We believe gold is the ultimate hedge against financial, economic, monetary, and geopolitical risks. Its recent performance reflects the current state of the world across these dimensions, and by all accounts, it still has significant potential for growth. We think this gold bull market has only just begun.”

Strategic Advisor and mining entrepreneur Sean Roosen added, “I truly believe Streamex is the next evolution in mining finance, like royalty/streaming companies and ETFs in the past, but with greater reach. It opens a new channel for funding and investor access to commodity and mining assets, using modern tools to solve old problems, attracting capital, increasing transparency, and supporting project development. Built by a team with deep industry experience, Streamex will be a game-changer for how mining connects with the next generation of investors.

Streamex’s executive and leadership team, led by CEO Henry McPhie and Chief Investment Officer Mitch Williams, brings extensive expertise across crypto, technology, institutional investing, and scaling multi-billion-dollar companies. Their backgrounds include leadership roles at OppenheimerFunds, Credit Suisse, Wafra Inc., Laconic, Rio Tinto, NexMetals and Freeport McMoRan. The company is also backed by a world-class group of strategic advisors, including renowned entrepreneur Frank Giustra, Osisko Group Co-Founder Sean Roosen, tech and commodities investor Mathew August, and Parcl Co-Founders Trevor Bacon and Kellan Grenier.

Streamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq

Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig”) and Streamex Exchange Corporation(“Streamex”), collectively referred to as the combined company, today announced successful completion of the previously disclosed share exchange transaction and executive leadership changes, forming a company specializing in the tokenization of real-world assets, with a focus on bringing commodities on-chain.

Key Highlights of the Transaction:

  • Streamex Exchange Corporation, a British Columbia corporation, will become a wholly owned subsidiary of BioSig through an exchange of outstanding shares of Streamex for new shares of BioSig common stock.
  • The combined company will be led by Mr. Henry McPhie, Co-Founder and CEO of Streamex, who will serve as Chief Executive Officer and join the Board of Directors, guiding the organization through its next phase of growth.
  • Mr. Morgan Lekstrom, Co-Founder and Chairman of Streamex, will serve as Chairman of the Board of the combined company.
  • Mr. Anthony Amato, current CEO of BioSig, will transition from his role as Chief Executive Officer and continue to support the combined company as a member of its Board of Directors.
  • Of highlight, Streamex is strategically positioned within the US$142.851 trillion global commodity market, aiming to unlock new value by bringing commodities on-chain through secure and scalable real world asset tokenization solutions.

Together, Henry and Morgan with Anthony’s support will lead the combined company through its next phase of strategic growth, bringing deep industry expertise and a shared vision for transforming the future of real-world asset tokenization in the commodities space.

CEO of the combined company Henry McPhie commented, “This is a landmark moment for Streamex and a major step forward for the tokenization industry. Joining forces with BioSig and entering the public markets will position us to accelerate growth, scale our technology and expand our influence within the tokenization and commodities industries. I am extremely proud of what the Streamex and BioSig team has been able to accomplish so far and am excited for what is to come.”

Strategic Advisor Additions:

Mr. Frank Giustra has agreed to join as a Strategic Investor and Advisor on Commodities.

  • Founder of Wheaton Precious Metals ($37B)
  • Founder of GoldCorp, acquired by Newmont ($57B)
  • Founder of LionsGate Films ($2B)

Mr. Mathew August has agreed to join as a Strategic Advisor on US Capital Markets.

  • Executive Chairman of Atlas Capital Partners a New York, NY based single family office investment firm and merchant bank
  • Active Venture Capitalist with significant investments within the Defense Tech, FinTech, Aerospace and other diversified industries

About Streamex Exchange Corporation

Streamex is a real-world asset (RWA) tokenization company focused in the commodities space. With the goal to bring commodity markets on chain, Streamex has developed primary issuance and exchange infrastructure that will revolutionize commodity finance. Streamex is led by a group of highly successful and seasoned executives from financial, commodities and blockchain industries.

Streamex believes the future of finance lies in tokenization, innovative investment strategies, and decentralized markets. By merging advanced financial technologies with blockchain transparency, Streamex has created infrastructure and solutions that enhance liquidity, accessibility, and efficiency. Streamex’s goal is to bridge the gap between traditional finance and the digital economy, unlocking new opportunities for investors and institutions worldwide.

Terms of Share Exchange

  • In exchange for 100% of their shares of Streamex, existing Streamex shareholders will be entitled to receive 75% of the fully diluted BioSig common stock outstanding on the date of the share exchange agreement.  Initially, upon the closing, pursuant to Nasdaq listing rules, the Streamex shareholders will be entitled to receive 19.9% of the outstanding BioSigcommon stock pre-transaction.  BioSig will then seek a vote of its current shareholders to approve the transaction; if such approval is obtained, the Streamex shareholders will have the right to receive in the aggregate the full number of shares of BioSig common stock equaling 75% of the fully diluted BioSig common stock pre-transaction.
  • After shareholder approval, if obtained, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding.  

Effective immediately, the Board of Directors of the combined company will be comprised of six members, four designated by BioSig, who are Anthony Amato, Chris Baer, Donald F. Browne, Steven E. Abelman and two designated by Streamex, who are Mr. McPhie and Mr. Lekstrom(who will also be Chairman of the combined company’s board).

To the extent required by NASDAQ’s change of control rules and regulations, the combined company will file an initial listing application for its common stock.

Transaction Highlights

  • Technology Stack – A fully developed and operational primary issuance and decentralized exchange infrastructure for on chain commodity markets.
    • Commodity-focused real-world asset tokenization infrastructure and financing platform.
    • Tokenization and financing infrastructure for streamlining the investment process, increasing capital availability for companies and opportunities for investors.
    • Gain access to real-world assets with the ease and security of crypto. Diversify  portfolios with tangible investments in a digital-first world.

Figure 1: The Streamex Ecosystem

Figure 2: The Streamex Platform

Streamex and BioSig Appoint Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer (CIO)

Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig”) and Streamex Exchange Corporation(“Streamex”), collectively referred to as the combined company, today announced the appointment of Mitch Williams, CFA, as Chief Investment Officer significantly bolstering the companies’ leadership team and advancing the mission to tokenize real world assets and bring commodity markets on-chain.

Key Highlights of the Appointment:

  • Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex will be appointed Chief Investment Officer of the combined company.
  • Mr, Williams, brings over 20 years of experience in capital markets, having held senior executive roles at OppenheimerFunds, and Wafra Inc.
  • At Wafra Inc., Mr. Williams, grew Global Equity assets by more than 3-fold and consistently delivered asymmetric returns with top-quartile performance over all rolling five-year periods.
  • At OppenheimerFunds, Mr Williams was a highly-ranked equity analyst and led the firm’s flagship Value Fund.
  • Mr. Williams will help lead Streamex in its strategic positioning within the US$142.851 trillionglobal commodity market, aiming to unlock new value by bringing commodities on-chain through secure and scalable real world asset tokenization solutions.

As CIO, Mitch will lead the combined companies’ strategic vision and commodity tokenization initiatives, while overseeing key areas and reporting directly to Henry McPhie the Chief Executive Officer.

Mitch commented, “As an early investor in Streamex and later a Strategic Advisor I have been consistently impressed with Henry, Morgan, and the team and the innovative platform they’ve built.  As a believer in disruptive technology, I see RWA tokenization as an incredibly scalable technology.  For me it is a leap forward in finding real world applications for blockchain- a technology whose value has only begun to be realized.  As an investor, I see Streamex as one of the few pathways for investors interested in both a hedge against fiat currency regimes and a recurring revenue model.”

“We are thrilled to welcome Mitch, as our new Chief Investment Officer,” said Henry McPhie Chief Executive Officer of the combined company. “Mitch’s exceptional record of delivering disciplined, high-return investment strategies over his career at large New York funds paired with his collaborative leadership style perfectly complements our culture and growth ambitions. I am confident that his vision will unlock new opportunities for our shareholders, and I couldn’t be happier to have him join our leadership team.”

About Mitchell Williams, CFA

In his over two decades on Wall Street, Mitch has had a front row seat for disruptive technologies and market innovation.  From his early role during Web 1.0 at Credit Suisse on the Internet Financial Services team to high-profile positions at OppenheimerFunds and Wafra Incmanaging multi-billion dollar domestic and Global teams and portfolios, Mitch has driven consistent value creation for both his clients and employers.  

At Wafra, Mitch grew Global Equity assets by more than 3-fold during his tenure, delivering asymmetric returns characterized by upside capture consistently above 100% and downside capture below 100%. Under his leadership Wafra achieved top-quartile performance for every rolling five-year period his team managed the Global Equity strategy. At OppenheimerFunds, he was a highly-ranked analyst and took a leading role in managing the firm’s flagship Value equity fund.

As Chief Investment Officer at Streamex, Mitch will apply his deep capital markets expertise and strategic vision to shape the firm’s direction. Prior to this role, he served as a Strategic Advisor on Capital Markets, working closely with Streamex founders Henry McPhie, Morgan Lekstrom, and Mathew August to develop and implement transformative business strategies.

Outside of his professional commitments, Mitch is an active mentor and speaker. He volunteers with the Michael Price Student Investment Fund at NYU’s Stern School of Business and has spoken on investing at numerous leading universities. He holds an MBA from NYU Stern, where he was awarded the Stern Fellowship, and a BA from the University of Florida.

NEWS


BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1.1B USD in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Markets

3 days ago

BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

Jun 9, 2025

BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

Jun 4, 2025

CORRECTION: Streamex and BioSig Appoint Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer (CIO)

May 28, 2025

BioSig Appoints Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer

May 28, 2025

Streamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq

May 28, 2025

BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

May 5, 2025

BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

Mar 26, 2025

BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel

Oct 22, 2024

BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation

Jul 31, 2024

BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024

Jul 25, 2024

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

Jun 10, 2024

BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 30, 2024

BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders

May 21, 2024

BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent  

May 3, 2024

BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

Apr 30, 2024

BioSig Engages Consulting Firm for Business Model Strategies

Apr 4, 2024

MANAGEMENT

Henry McPhie

Henry McPhie

CEO

Henry McPhie is a seasoned entrepreneur and visionary technologist with a strong track record of building innovative companies at the intersection of blockchain and finance. He is the Co-Founder and Chief Executive Officer of Streamex, where he leads the company’s mission to revolutionize real-world asset tokenization and bring commodities on-chain through cutting-edge blockchain solutions.

Prior to founding Streamex, Henry Founded Lynx Web3 Solutions, a blockchain incubation and software development firm that supported early-stage Web3 projects with the tools, infrastructure, and strategic guidance needed to scale. Henry was also the founder of FatCats Capital, a Solana-based NFT project that quickly rose to become the third largest NFT project in the world at the time of its launch. Under his leadership, FatCats cultivated a vibrant global community of over 100,000 members, setting new standards for value creation in the NFT space.

With a background in engineering, Henry holds a degree in Mining Engineering from McGill University. He brings a rare combination of technical acumen, product vision, and community-building expertise to every venture he leads, and remains deeply committed to advancing the adoption and utility of blockchain technology and tokenization across industries.

Ferdinand Groenewald

Ferdinand Groenewald

Interim CFO

Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at Financial Consulting Strategies LLC; a Controller, VP-Finance & Accounting Officer at Sadot Group, Inc. and a Chief Financial Officer at the same company; and Chief Accounting Officer & VP-Finance at Muscle Maker Development LLC. Mr. Groenewald obtained an undergraduate degree from the University of South Africa.

Mitchell Williams, CFA

Mitchell Williams, CFA

CIO

Mitchell Williams, CFA is the Chief Investment Officer of Streamex, bringing over 20 years of experience at the forefront of Wall Street, where he has consistently driven performance through strategic insight, innovation, and disciplined investment management. Mitch began his investment career during the Web 1.0 era at Credit Suisse, where he was part of the Internet Financial Services team. He went on to hold senior Executive roles at OppenheimerFunds and Wafra Inc., managing multi-billion dollar global and domestic equity portfolios and leading high-performing investment teams.

At Wafra, Mitch grew assets under management more than threefold, delivering asymmetric returns with consistent upside capture above 100% and downside capture below 100%. Under his leadership, Wafra’s Global Equity strategy achieved top-quartile performance across every rolling five-year period. At OppenheimerFunds, he was a highly ranked equity analyst and sole portfolio manager for one of the firm’s flagship funds.

Before becoming CIO, Mitch served as Strategic Advisor on Capital Markets for Streamex, collaborating closely with founders Henry McPhie, Morgan Lekstrom, and Mathew August to help craft the company’s forward-looking investment strategy. In his current role, he leverages deep capital markets expertise to lead investment strategy and guide Streamex’s mission to tokenize real-world assets within the commodities space.

Mitch is also an active mentor and speaker, volunteering with the Michael Price Student Investment Fund at NYU Stern School of Business, where he earned his MBA as a Stern Fellowship recipient. He holds a BA from the University of Florida and has spoken on investing at several top universities.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND FIVE HUNDRED USD BY LFG EQUITIES CORP FOR A ONE DAY BSGM AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

VBIX

***Sponsored by LFG Equities Corp.

Viewbix Inc.

Viewbix Announces Uplist to Nasdaq

_________________

Hello Everyone,

We have something really exciting for tomorrow’s session.

This is a company that we have never have profiled before on this newsletter.

Recent MAJOR developments have made this next company one to watch ahead of Thursday’s session.

This one just uplisted to the Nasdaq from the OTC. It’s something a lot of company’s talk about but few are able to accomplish. If it was that easy then everyone would be doing it. Obviously this a company with a vision and is in the process of executing.

Pull up VBIX right away and research it ahead of Thursday’s session.

Viewbix is a digital advertising company operating in Israel, with two main divisions: Ad-Search and Digital Content. The Ad-Search division develops software solutions for automating, optimizing, and monetizing online advertising campaigns by directing internet user traffic to search engines. The Digital Content division focuses on creating, editing, and marketing content in various languages to different audiences, generating revenue through advertising on various platforms.

Lets take a look at some of the catalysts to dive into

***Limited Float: (VBIX) has fewer than 4.5 Mln shares listed as available to the public according to FinViz. We have seen in the past what the low float plays can do when they get some momentum behind it.

***Recent Momentum: In the last week, VBIX moved approximately 78%, from $2.42 on June 25 to $4.33 by July 3, now we know the capability.

***Nasdaq Visibility Boost: The recent uplisting of VBIX to the Nasdaq Capital Market enhances its visibility and access to institutional radars as it scales its ad-tech infrastructure.

***Dual Platform Strategy: VBIX operates two execution-focused platforms—Gix Media and Cortex—designed to capture, optimize, and monetize high-intent traffic for advertisers and publishWith a limited float, recent momentum, and positioning inside a sector on track to grow around 550%, Viewbix Nasdaq: VBIX is aligning its strategy in the evolving world of digital advertising. Its recent uplisting to the Nasdaq, combined with a clear focus on scaling its search and content platforms globally, sets the stage for  VBIX as it aims to enhance its presence in a rapidly growing market.

***Global Content Reach: Through Cortex, VBIX deploys multilingual content across major digital platforms, aligning with rising digital consumption across emerging and mature markets worldwide.

***Expansion Plans: The board of VBIX has announced plans to actively explore new sectors and initiatives to expand its digital advertising capabilities for the next phase of growth. The board’s plans to explore additional sectors further underscore the company’s intent to build on its current strengths while preparing for the next phase of digital advertisers.The board’s plans to explore additional sectors further underscore the company’s intent to build on its current strengths while preparing for the next phase of digital advertisers.

Through Gix Media, Viewbix partners with leading search engines worldwide, developing and distributing software that efficiently reaches internet users.

This platform captures and routes high-intent traffic, allowing advertisers to maximize campaign efficiency while enabling publishers to tap into new, targeted revenue streams.

In a digital landscape where customer acquisition costs are climbing, VBIX’s Search Platform is engineered to automate, optimize, and transform user acquisition pipelines into cash flow.

logo

Through Cortex, Viewbix creates, edits, and markets multilingual content for diverse audiences, deploying it across major digital advertising and marketing platforms.

Each piece of content is built to generate measurable advertising revenue, allowing publishers and advertisers to benefit from scalable, monetizable ecosystems.

With its multilingual capabilities, Cortex positions VBIX to support global campaigns without geographical limitations, aligning perfectly with rising digital consumption across both emerging and mature markets.

Cortex Media Group was born to provide unique content that adds value to readers’ everyday lives. Run by a world-class team of motivated and creative writers and editors they strive to produce content that involves and intrigues their readers.

As the proud parent company of Samyo News, they take high-end content very seriously. Cortex offers carefully written, informative, and entertaining content. They boast over 20 million monthly visitors.

Their seven unique websites offer content on a wide range of topics including travel, history, culture, animals, and more. With content optimized for all platforms, readers can enjoy our content absolutely anywhere.

Their primary focus is to adapt, research, and write material that grabs our readers and launches them into an alternate reality — one where all their dog-loving needs are met, and they know exactly what cars are expected to be released next year. Their passion is creating content that matters, no matter who you are.

Using cutting-edge technology software and analysis we are able to accurately select the most potentially successful content.

Viewbix Announces Uplist to Nasdaq

Tel Aviv, Israel, June 04, 2025 (GLOBE NEWSWIRE) — Viewbix Inc. (OTC: VBIX) (“Viewbix” or the “Company”), a global developer of ad-tech innovative technologies, today announced that its shares of common stock were approved for listing on the Nasdaq Capital Market (“Nasdaq”). The Company expects that its shares of common stock will begin trading on the Nasdaq under the symbol “VBIX”, at the opening of trading on or about June 5, 2025, subject to continued compliance with the exchange rules.

The Company’s shares of common stock were previously quoted on the OTC Markets, Pink Tier and ceased to be quoted at the close of business on June 4, 2025. Stockholders of the Company do not need to take any action prior to the listing of the Company’s shares of common stock on the Nasdaq.

“Uplisting to the Nasdaq marks a significant milestone for Viewbix,” said Amihay Hadad, Chief Executive Officer of Viewbix. “We expect that the Nasdaq listing will provide Viewbix with greater exposure to one of the largest capital markets in the world and hope to enhance our visibility and accelerate our growth trajectory.”

‍

Management

‍

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY VBIX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.